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iv. Abstract 
Ovarian cancer is the deadliest gynaecologic cancer in New Zealand. Its high mortality rate 
is due to the fact that it is usually diagnosed at an advanced stage. Advanced ovarian 
cancer is less responsive to current cytotoxic treatment. Thus, there is an urgent need for 
novel anti-cancer drugs that can improve patient longevity and quality of life. One of the 
clinical features of advanced ovarian cancer is the growth of secondary tumours due to the 
highly metastatic nature of the disease. Cancer cells disseminate from the ovary, some 
form cell clusters that travel through the abdominal cavity by physiological movement of 
body fluid and then deposit on the abdominal wall and internal organs to generate 
secondary tumours. The exact mechanisms of how these cells metastasize are unclear, but 
prognosis typically worsens if levels of vascular endothelial growth factor (VEGF) are 
elevated. This study investigated the anti-tumour activities of naturally occurring food 
compounds resveratrol, acetyl resveratrol and (-)-Epicatechin-3-gallate (EGCG), in cell 
spheroids/clusters of ovarian cancer. It also examined the protein expression of various 
proteins involved in the NF-κB signalling pathway. This pathway has been suggested to 
mediate the secretion of VEGF and is a possible target for the naturally occurring 
compounds. Results show that resveratrol and acetyl resveratrol reduce cell growth and 
cellular metabolism in a dose-, time- and cell line- dependent fashion. In addition, the 
reduction of VEGF is also dose-, time- and cell line- dependent. Paradoxically, another 
angiogenic protein interleukin-8 (IL-8) secretion is increased. Resveratrol and acetyl 
resveratrol attenuate the expression of NF-κB but this effect is cell line specific. EGCG has 
limited effect on cell growth, cellular metabolism and the secretion of VEGF and IL-8. These 
findings suggest that resveratrol and its derivative may have the ability to supress the 
angiogenic activity of ovarian cancer cells and warrant further in vivo study.  
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Chapter 1 
Introduction. 
1.1 Overview. 
Ovarian cancer is the deadliest gynaecological cancer worldwide, with approximately 69% 
of sufferers dying from the disease (Lengyel, 2010). According to the most recent survey, it 
is the fifth most common cause of cancer related deaths in New Zealand women (Ministry 
of Health, 2013). Ovarian cancer can be classified into two broad groups Type I and Type II 
and it is Type II that is of most concern. Around 75% of all diagnosed ovarian cancers fall 
into this group, and these are epithelial-derived tumours that develop quickly, are very 
aggressive and have a very low early stage detection rate (Cho and Shih, 2009). The current 
treatment options for ovarian cancer are very limited. It is either treated with aggressive 
surgery, chemotherapy or a combination of the two (Lengyel, 2010). There are many 
pitfalls of surgery with the most common being incomplete removal of tumorous cells and 
post-operative complications (Shih and Chi, 2010). Chemotherapy with the platinum 
compounds carboplatin or cisplatin and with paclitaxel is non-specific and thus extremely 
toxic to non-cancerous cells. Furthermore, the development of high rates of resistance to 
these drugs is also problematic in ovarian cancer cells (Lengyel, 2010).  Therefore, the 
search for more appropriate targeted cancer cell therapies with minimal adverse effects is 
ongoing (Shukla & Singh, 2011).  
Many natural food compounds are of interest as potential chemotherapeutic and 
chemopreventive agents as they appear to have anti-cancer properties and are nontoxic to 
homeostatic cells. Of these, resveratrol and EGCG are extremely promising as they have 
been shown to affect multiple signalling pathways to reduce tumour growth in a variety of 
human cancers (Singh et al., 2011, Athar et al., 2009). However, these compounds are as 
yet unproven in ovarian cancer early metastasis and the mechanisms for their potential 
anti-carcinogenic properties in early metastatic ovarian cancer are unclear. 
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1.2 Cancer. 
Cancer is one of the leading causes of disease and death in developed countries. In 2008 it 
was estimated that 12.7 million new cases of cancer were diagnosed worldwide, and 7.6 
million people died from the disease (Ferlay et al., 2010). In 2012, those figures had 
increased to 14.1 million new cases and 8.2 million deaths (Ferlay et al., 2013), and cancer 
rates are predicted to continue to rise in the future, it is estimated that 22.2 million new 
cases annually will be diagnosed by 2030 (Bray et al., 2012). As the prevalence of cancer 
increases with age, the steady incline of disease incidence worldwide is in part due to a 
progressively aging population (Bray et al., 2012). Another key contributing factor to the 
commonness of cancer is its ability to adapt and circumnavigate current available therapies 
(Ferlay et al., 2010). Therefore, there is great impetus to elucidate the fundamental 
survival mechanisms of cancer and develop effective treatment options. 
Cancer is a class of genetic diseases that are characterised by uncontrolled cell growth. 
There are over 100 different types of cancers originating in all areas across the human 
body and each of these can possess their own physiology. There are also many differing 
subtypes within each type of cancer and to further complicate matters each subtype can 
also have its own specific physiology. However, there have been certain common 
characteristics identified amongst cancer cells that they must adopt to enable their 
growth. Firstly, cancer cells are resistant to programmed cell death, whilst normal cells 
eventually undergo apoptosis, in cancer cells intrinsic apoptosis signalling never 
eventuates. Cells also possess replication immortality that is they are not restricted to a 
limited number of divisions, and have persistent proliferative signalling, which is arguably 
the most fundamental of all the traits. Cancer cells are able to induce angiogenesis, the 
formation of new blood vessels, and are capable of invasion and metastasis. Cancers can 
also evade immune destruction, growth suppressors and deregulate cellular metabolism 
(Hanahan and Weinberg, 2011). In addition to this, there are also common underlying 
mechanisms that enable the cells to acquire these characteristics. These are inflammation, 
genetic instability and tumour microenvironment alterations (Hanahan and Weinberg, 
2011).  
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1.2.1 Ovarian Cancer. 
Ovarian cancer is cancer of the female reproductive organs called ovaries. There are two 
ovaries in the female body located in the lower pelvic region of the peritoneal cavity. They 
are connected to the uterus by fallopian tubes and are responsible for producing eggs for 
reproduction and generating the majority of the female hormones. Ovarian cancer stems 
from cells on the epithelium (or outer surface) of the ovary, or more rarely from the sex-
cord stromal cells which produce hormones or germ cells (Fig. 1.1).  
The pathogenesis of ovarian cancers is largely unknown, but a current hypothesis is that 
they remain localised to the ovary during early development. As development continues 
the cancer cells slough off the ovary into the peritoneal cavity, and this is frequently 
associated with the formation of ascetic fluid (fluid in the peritoneal cavity). Once floating 
in the ascetic fluid the cells aggregate to form spheroids or clusters, which then 
disseminate throughout the abdominal cavity (Fig. 1.2). This mode of dissemination differs 
from classic patterns of metastasis, and its unique biological behaviour is largely 
responsible for the insidious nature of ovarian cancer (Naora and Montell, 2005). Thus, the 
cancer is able to directly metastasize to other organs also located in the peritoneal cavity 
(Cho and Shih, 2009).  
 
Figure 1.1. The female ovary. Most cases of ovarian cancer arise from epithelial cells on the 
surface of the ovaries. Germ cells and sex cord-stroma cells give rise to only 10% of ovarian 
cancer. Image adapted from 
http://www.pathinformatics.com/smallgroups/reproductive/female/fig5c.htm 
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The spheroids formed during early development are described as being imperative for 
free-floating cell survival and growth and believed to significantly hinder the treatment of 
late stage ovarian cancer (Shield et al., 2009). The origins of ovarian cancer are unknown 
but a well-accepted theory is that ‘incessant ovulation’ is primarily the cause. Essentially, it 
proposes that due to the process of ovulation the epithelium is required to repair itself 
every month. These epithelial cells, therefore, have to replicate more often which 
increases the likelihood of genetic damage.  
 
Figure 1.2. Proposed model of early metastasis of ovarian cancer. During progression stage 
1 cancerous cells shed off the ovarian tumour into the ascites within the peritoneal cavity. 
At progression stage 2 the cells aggregate to form spheroids/clusters which are suggested 
to increase the cancers metastasis. Progression stage 3 is when the spheroids form 
secondary solid tumours. Image from Shield et al., 2009. 
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The clinical progression of ovarian cancer is divided into four stages; at stage I the 
malignancies are restricted to the ovaries, stage II encompasses its localised spread to 
adjacent pelvic organs and tissues, at stage III the cancer presents on tissues or organs of 
the upper abdominal cavity and at stage IV the cancer has metastasized to distant extra-
peritoneal sites (Fig. 1.3). About 90% of ovarian cancers are epithelial derived carcinomas. 
These can be further classified as either serous, endometrioid, clear cell or mucinous, 
based on their morphological appearance (Su et al., 2013). Ovarian cancers are categorized 
into two broad groups Type I and Type II based on their histology, tumour grade and other 
general characteristics. The tumour grade describes the proportion of solid tumour growth 
compared to glandular or papillary structures, also described as the amount of 
‘differentiation’ (Silverberg, 2000). Type I ovarian tumours grow relatively slowly; they are 
often large and localised to the ovary making them easier to detect. They include serous, 
endometrioid, mucinous, and some clear cell carcinomas that are of a low grade (1 or 2, 
i.e. less than 50% solid tumour). Unfortunately, they represent fewer than 25% of 
aggressive ovarian cancers. Type II ovarian tumours, on the other hand, are mostly grade 
3-4 and have almost always metastasized by the time of diagnosis. Accordingly, they are 
thought to have a quicker development rate than Type I, be much more aggressive and 
harder to detect at an early stage (Cho and Shih, 2009).  
Ovarian cancer has been found to have a higher incidence rate in Caucasian women living 
in developed countries (Merritt and Cramer, 2010). Occurrence also increases with the 
onset of menopause and increase in age up to 80 years (Ries et al., 2008). Ovarian cancer 
also has a high level of familial heredity, with the probability of it developing within a 
lifetime increasing from less than 2% for an average woman to 7% for women who have at 
least two family members who had the disease (Schildkraut and Thompson, 1988). The 
hereditary breast-ovarian cancer BRCA mutation also increases the likelihood of ovarian 
cancer by approximately 30% for carriers (Whittemore et al., 1997), and the estimated 
population frequency of the mutation is 0.1% (Evans, 2012). A number of other oncogenes 
have been found to be associated with ovarian cancer besides BRCA. Of these, the most 
prominent include KRAS, BRAF and TP53 (Nakayama et al., 2008). The tumour suppressor 
protein p53, which has a number of cellular roles including control of the cell cycle and 
stimulation of apoptosis in response to DNA damage. p53 is mutated in 30% of ovarian 
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cancers, which results in overexpression in about 50% of these cases (Holschneider and 
Berek, 2000). 
 
 
Figure 1.3. The stages of clinical progression of ovarian cancer. Stage 1 –The cancer is 
limited to the ovaries. Stage 2 –Cancer spreads into the pelvic region. Stage 3 –The cancer 
metastasizes into the abdominal region. Stage 4 –The cancer reaches distant organs e.g. 
the lungs or liver.  
Image from http://www.kkh.com.sg/HealthPedia/Pages/GynaecologicalCancersOvarian.aspx 
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Ovarian cancer has a high mortality rate largely due to detection difficulty. Its symptoms 
are vague and often mistaken for other illnesses, resulting in about 70% of cases only being 
diagnosed at advanced stages where the survival rate is diminished to just 30% (Cho and 
Shih 2009). This limits the capacity for successful treatment and more than 50% of women 
do not survive five years after diagnosis (Coleman et al. 2011). 
1.2.2 Current treatment options for Ovarian Cancer. 
1.2.2.1 Surgical Management. 
Surgery is currently one of the standard treatment options for ovarian cancer. For 
epithelial ovarian cancers, as a majority are at an advanced stage by the time they are 
diagnosed, maximal cytoreduction surgery (or debulking) is usually the initial treatment 
(Shih and Chi, 2010). This form of surgery involves the removal of tumours greater in size 
than 1cm, complete removal of these tumours is known as optimal cytoreduction. The 
correlation between debulking and improved outcome was first documented in 1975, 
where it increased patient survival by over a year (Griffiths, 1975). The theory behind 
debulking is that larger tumours have poorer blood supply and do not receive optimal 
doses of chemotherapy and therefore, do not respond to treatment, whereas the smaller 
tumours left behind should be susceptible to chemotherapy (Shih and Chi, 2010). The size 
of the tumours left behind is regarded as the strongest prognostic factor for post-operative 
survival (Aletti et al., 2006). Maximal cytoreduction is limited by the extent of the disease, 
many surgeons will not remove tumorous sections of the bowl, diaphragm or portal triads 
of the liver (Aletti et al., 2006), liver parenchymal or lung metastases can also preclude 
optimal debulking (Shi and Chi, 2010). Debulking is quite a radical surgery and nearly 
always includes the removal of the ovaries, fallopian tubes, uterus and the lining of the 
peritoneal cavity known as the omentum (Aletti et al., 2006). This of course renders the 
women barren and reduces the amount of oestrogen and progesterone produced. This 
reduction in hormones can lead to early onset of menopause which in turn is accompanied 
by other complications such as osteoporosis, increased risk of heart disease and other 
menopausal discomforts.  
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For the remaining 10% of ovarian cancers that are not epithelial derived surgery is also the 
first line of treatment. However, due to germ cell and sex cord stromal tumours usually 
being diagnosed at an early stage, prognosis after surgery is excellent and adjuvant 
treatment is often not required (Colombo et al., 2009). Furthermore, there is a higher 
chance that fertility may be retained post-surgery via the removal of only the affected 
ovary and fallopian tube. This is important as many women affected with these kinds of 
malignancies are preadolescent or young adults (Colombo et al., 2009). In the rare 
instances where non-epithelial ovarian cancers present at an advanced stage optimal 
cytoreduction is undertaken as described above (Colombo et al., 2009). 
1.2.2.2 Chemotherapy. 
The platinum-based drug cisplatin has been used as a first-line chemotherapy for over 20 
years (Burger et al., 2011). Cisplatin is the cis-isomer of the diamminedichloroplatinum(II) 
complex that is, a platinum ion coordinated by two chloride atoms and two ammonia 
groups with a net charge of +2. The antiproliferative properties of cisplatin were first 
observed by Rosenberg and colleagues in Escherichia coli who then suggested its potential 
as an anti-cancer drug (Rosenberg et al., 1965). Cisplatin’s cytotoxic effects are conferred 
by its ability to bind directly to DNA (Knox et al., 1986). This interferes with the DNA 
replication and transcription processes via cross-linking of complimentary DNA strands at 
adjacent guanine bases (Roberts and Pascoe, 1972). The first evidence of cisplatin 
effectively reducing ovarian cancer growth was documented in 1974, in what was in fact 
the first evidence of its antitumor effect on any cancer (Tattersall, 2002). Despite its 
worldwide use cisplatin has limited efficacy due to negative side-effects and the 
development of resistance in tumour cells. Its major reported side-effect is nephrotoxicity 
(Gonzales-Vitale et al., 1977); others are neurotoxicity, ototoxicity, renal toxicity and 
vomiting (Knox et al., 1986).  
Due to the toxicity of cisplatin, other derivatives have been produced and investigated. Of 
these carboplatin is the only other platinum based compound commonly used worldwide 
(Lebwohl and Canetta, 1998). Structurally carboplatin is similar to cisplatin however, 
instead of the chloride groups carboplatin possesses a more stable ligand, the cyclobutane 
ring, thereby lessening its nephrotoxic potential (Knox et al., 1986). Significant attenuation 
of ovarian cancer growth was recorded during the first clinical trial of carboplatin (Lebwohl 
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and Canetta, 1998). The efficacy of carboplatin has been shown to not significantly differ 
from cisplatin and due to its lower toxicity has become the more preferred 
chemotherapeutic drug of the two platinum based complexes (Ozols, 1999).  
However, due to the quite high occurrence of resistance to platinum based therapy in 
ovarian cancer researchers began looking at the effectiveness of administering 
combinations of other chemotherapeutic drugs with a platinum based compound. 
Paclitaxel was discovered to be active in platinum resistant patients and became a 
commonly used combination partner (Ozols, 1999). Paclitaxel is a mitotic inhibitor first 
extracted from bark of Taxus brevifolia. It binds to polymerized tubulin, promotes and 
stabilizes polymerized microtubules thereby arresting cells in mitosis (Cragg and Newman, 
2004). To begin with paclitaxel, in conjunction with cisplatin, was the favoured 
combination for ovarian cancer treatment; today it is paclitaxel and carboplatin that are 
the more common first line treatment drugs (Tattersall, 2002). However, the toxicity of 
paclitaxel is also quite excessive. Adverse side effects include peripheral neuropathy, 
myelosuppression, arthralgias, myalgias and skin problems. Therefore, clinical doses of 
paclitaxel are limited to achieve antitumor activity, whilst reducing the severity of adverse 
effects (Cella et al., 2003). 
Although the three afore-mentioned chemotherapeutic compounds are the most widely 
used treatments for epithelial ovarian carcinomas they are not the only ones. Other 
chemotherapy agents include docetaxel, cyclophosphamide, irinotecan and melphalan. For 
the management of advanced germ cell or stromal tumours a combination of cisplatin, 
etoposide and bleomycin is the preferred treatment (Colombo et al., 2009). Although 
surgery followed by adjunct chemotherapy is the cornerstone of ovarian cancer treatment 
there are two other options available. One is hormone therapy, which utilises drugs that 
attenuate oestrogen secretion as oestrogen is a recognised inducer of cell proliferation. 
Hormone therapy is more often used to treat stromal tumours (Simpkins et al., 2013). The 
other is radiation, where tumours are targeted with beams of radiation which damage the 
cancers DNA causing cell death, this treatment is mostly utilised on recurring ovarian 
carcinomas (Brown et al., 2013). 
As ovarian cancers have a high mortality rate, first line treatments are extremely harsh and 
the incidence of recurrence is extremely likely, it is with great impetus that the search for 
preventative and or more effective treatment methods continues. 
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1.3 Natural Dietary Polyphenols. 
1.3.1 Resveratrol. 
Many natural food compounds are of interest as potential chemotherapeutic and 
chemopreventive agents as they appear to have anti-cancer properties and be nontoxic to 
normal cells. Such compounds are also readily available due to their accessibility and wide 
distribution in edible plants (Shukla and Singh, 2011). The polyphenolic phytoalexin 
resveratrol is one such compound produced by plants as a defence mechanism against 
fungal attack (Savouret and Quesne, 2002). It is found in foods such as blueberries, 
peanuts, mulberries and cocoa, however, it is most abundant in the skin of red grapes and 
its presence in red wine in relatively high concentrations has turned resveratrol into a 
compound of great interest (Athar et al., 2009). It was initially isolated from the poisonous 
roots of white hellebore in 1940 and in 1963 from the roots of a centuries old traditional 
Asian medicinal plant Polygonum cuspidatum known as Ko-jo-kon (Baur and Sinclair, 2006). 
Resveratrol consists of two phenolic rings linked together by a double bond (Fig. 1.4) this 
enables it to exist as two diastereomeres, however it is trans-resveratrol that occurs more 
often naturally (Kraft et al., 2009).  
There are a wide range of beneficial health effects attributed to resveratrol, including 
prevention of diabetes and Alzheimer’s, inhibition of inflammation and oxidative stress, and 
cardioprotective effects (Baur and Sinclair, 2006, Athar et al., 2009, Kraft et al., 2009). 
However, in the late 90’s, it was discovered that resveratrol was capable of therapeutic 
activity against cancer (Jang et al., 1997).  Since then, there have been copious studies 
relating to resveratrol and cancer treatment. Resveratrol’s anti-cancer properties have 
been shown in various human cancers such as skin cancer, lung cancer, liver cancer, breast 
and prostate cancers (Aggarwal et al., 2004, Athar et al., 2009, Bishayee and Dhir, 2009, 
Trapp et al., 2010). Resveratrol has been demonstrated to have anti-carcinogenic activity in 
all three stages of carcinogenesis, i.e. initiation (by regulating signalling pathways that 
control cell growth and division), promotion (via inflammation and angiogenic pathways) 
and progression (regulating metastasis) (Shukla and Singh, 2011). However, a majority of 
these studies have been conducted on either 2D monolayer human cell cultures or in vivo 
animal models. 
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1.3.2 Acetyl resveratrol. 
Analogues of resveratrol have also been subjects of chemopreventive and 
chemotherapeutic studies as many appear to possess the same characteristics as 
resveratrol whilst protecting the hydroxyl groups from oxygenation, it is suggested that 
this shields the compound from rapid metabolism in the liver and or increases cellular 
uptake (Colin et al., 2009). Therefore, it is possible that these derivatives may act as a sink 
from which resveratrol can be released as it has been noted that in vivo concentrations of 
other resveratrol analogues can be as much as ten times more than the native compound 
(Baur and Sinclair, 2006). In acetyl resveratrol (Fig. 1.5), the hydroxyl groups are acetylated 
thus producing a more stable compound and hydrophobicity is also increased. Therefore, it 
should be able to cross the cellular membrane more readily than resveratrol (Liang et al., 
2013).  
 
 
 
Figure 1.4. The chemical structures of (a) the trans-isomer of resveratrol. Image from Kraft 
et al., 2009. (b) the trans-isomer of acetyl resveratrol (3,5,4’-tri-O-acetylresveratrol). Image 
from Liang et al., 2013. 
 
 
 
 
(a) 
 
(b) 
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1.3.3 (-)-Epicatechin-3-gallate (EGCG). 
The dried leaves of Camellia sinensis are used to brew the second most consumed 
beverage in the world, tea. Tea is mostly available in three types black, green and oolong, 
green tea roughly accounts for 20% of tea consumed worldwide (Khan and Mukhtar, 
2008). Green tea has long been known to be beneficial to the health of humans; it has 
shown to be beneficial in the treatment of Alzheimer’s, diabetes, stroke and obesity (Singh 
et al., 2011). These benefits have been attributed to green tea’s polyphenolic compounds 
which make up circa 30% of its dried weight. In particular it is the flavanols (-)-
epigallocatechin-3-gallate (EGCG), (-)-epigallocatechin, (-)epicatechin-3-gallate, (-)-
epicatechin, (+)-gallocatechin and (+)-catechin that are most active (Ahn et al., 2003). The 
most prominent flavanol, in constituency and activity, is EGCG (Kim et al., 2007). EGCG (Fig. 
1.6) has also been shown to possess anticarcinogenic properties and has modulated 
tumour growth and/or spread in breast, skin, colon, lung and liver cancers to name a few 
(Lu et al., 2002, Ahn et al., 2003, McLoughlin et al., 2004, Singh et al., 2011, Zhang et al., 
2012). Like resveratrol, it has also been demonstrated that EGCG is capable of affecting 
multiple signalling pathways to effect cancer inhibition (Singh et al., 2011). However, there 
are few studies on the effects of EGCG on ovarian cancer and to the best of my knowledge 
there have been none conducted in a 3D model.  
 
Figure 1.5. The chemical structure of (-)-Epicatechin-3-gallate. Image from Khan and 
Mukhtar, 2008. 
25 
 
1.4  Vascular Endothelial Growth Factor (VEGF) and The 
Nuclear Factor kappa B (NF-κB) Signalling Pathway. 
VEGF is a glycoprotein that is significantly involved in angiogenesis. Angiogenesis is the 
physiological process of developing new blood vessels from already existing ones. This 
process is thought to be vital to the growth and survival of any malignant tumour (Shimizu 
et al., 2010). Overexpression of VEGF has been observed in ovarian cancer and is 
associated with poor prognosis for ovarian cancer sufferers (Yu et al., 2013). There is a 
strong possibility that VEGF is important for the metastasis of ovarian cancer and it has 
been shown that resveratrol and EGCG are capable of downregulating VEGF secretion 
(Spinella et al, 2006, Dann et al., 2009). 
Signalling pathways that control cell proliferation, survival and angiogenesis are of interest 
for the development of targeted therapy (Rayet and Gelinas, 1999). The NF-κB pathway 
appears to be quite prominent in the angiogenesis process and the growth of cancer cells 
(Athar et al., 2009). The NF-κB protein itself has been identified as a target of resveratrol 
and EGCG in other types of cancer (Ahmad and Mukhtar, 1999, Athar et al., 2009). 
Therefore, the NF-κB signalling pathway is a strong candidate for being the co-ordinator of 
VEGF secretion in metastatic ovarian cancer. 
1.5 Three-Dimensional in vitro model. 
Since its development in 1907, two-dimensional (2D) cell culturing has been one of the 
cornerstones of research in cellular biology. 2D cell cultures are grown as a monolayer 
adhered to the bottom of a vessel with a medium for nutrition and are kept at body 
temperature (Breslin and O’Driscoll, 2013). However, of late the correlation of 2D culture 
results and in vivo situations has been called into question and other experimental setups 
such as three-dimensional (3D) cell cultures have begun to supersede the 2D model. It has 
been shown that 2D cultures can be significantly divergent in their cell-cell and cell-matrix 
interactions, morphology, receptor and oncogene expression, and differentiation from 
cultures grown in a more physiologically relevant 3D environment (Yamada and 
Cukierman, 2007). In normal epithelial cells organization, signalling and protein secretion in 
vivo is more similar to the 3D approaches than the 2D settings (Yamada and Cukierman, 
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2007). With regards to cancer biology, a distinct advantage 3D models have over 2D is the 
aggregates/spheroids produced are composed of cells with differing phenotypes, there are 
proliferating, non-proliferating and necrotic cells, this more closely resembles in vivo 
human tumours (Kim, 2005). 2D and 3D cultures also display drug response variances, for 
example when treated with a classical chemotherapeutic drugs 5-fluorouracil and 
tirapazamine cell viability was only 5% in the 2D culture whereas viability was up at 75% in 
the 3D model (Breslin and O’Driscoll, 2013).  
There are several different methods available when setting up 3D experiments; these 
include hanging drop, matrices and scaffolds, and microfluidic cell culture platforms 
(Breslin and O’Driscoll, 2013). However, the forced floating method was deemed the most 
appropriate for this investigation. This system was developed by Ivascu and Kubbies in 
2006 (Breslin and O’Driscoll, 2013) it is relatively simple to execute and highly 
reproducible. Plates are coated with a polymer to prevent cell attachment this promotes 
cell-cell interactions, thus, cells aggregate and form clusters/spheroids. This method was 
chosen for a variety of reasons. Firstly, the spheroids/clusters are easily accessible, in other 
systems that involve matrices or scaffolds it can be difficult to extract the aggregates 
formed (Breslin and O’Driscoll, 2013). It is compatible with investigations into drug efficacy, 
protein expression and identifying potential individualised cancer therapies (Yamada and 
Cukierman, 2007). Most importantly it mimics the microenvironment and cell formation of 
ovarian cancer aggregates in ascetic fluid much more closely than 2D models and other 3D 
models. Cell shape and environment have been recognised as important determinants of 
gene expression and behaviour of the cell (Kim, 2005).  
1.6 Hypothesis and Aims. 
Although the anti-carcinogenic properties of the natural dietaries resveratrol and EGCG 
have been extensively studied there is a lack of information regarding their effects on cell 
spheroids/clusters of ovarian cancer. I hypothesise that resveratrol, acetyl resveratrol and 
EGCG will exhibit anti-tumour activities in cell spheroids/clusters of ovarian cancer cells, 
and that these anti-tumour activities are mediated by NF-κB attenuation. 
 
27 
 
1.6.1 Aims.  
To study the effects of resveratrol, acetyl resveratrol and EGCG on cellular growth 
and metabolism in metastatic ovarian cancer. 
To study the combination effect of EGCG and resveratrol in metastatic ovarian cancer. 
To study the effect resveratrol, acetyl resveratrol and EGCG have on the secretion of VEGF 
and IL-8. 
To study the effect resveratrol, acetyl resveratrol and EGCG have on the activation of the 
NF-κB pathway. 
1.6.2 Model organisms. 
In this study, two immortal ovarian cancer cell lines were utilised SKOV-3 and OVCAR-5. 
These cell lines were chosen as it had previously been demonstrated that when grown in 
the 3D model the spheroids/clusters are morphologically quite different. The SKOV-3 
spheroids/clusters grow large enough to see with the naked eye and are very irregular in 
shape, whereas the OVCAR-5 spheroids/clusters are much smaller and much more uniform 
in shape.   
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Chapter 2. 
Materials and Methods. 
2.1  Materials. 
2.1.1 General solutions, buffers and media. 
2.1.1.1 10x Phosphate Buffer Solution (PBS). 
10x PBS was made up using the following, 1.4% Na2HPO4, NaH2PO4 for pH adjustment to 
7.4, 9% NaCl, 0.2% KCl and dissolved in MilliQ H2O up to 500ml. 
2.1.1.2 10x Non-sterile Trypsin-ethylenediaminetetraacetic acid 
(trypsin-EDTA). 
10x Trypsin-EDTA was made up using the following, 2.5% Trypsin powder, 0.75% EDTA, 
dissolved in 200ml 1x PBS. pH adjusted to 8 by adding NaOH. 
2.1.1.3 Tris(4-(dimethylamino)phenyl)methylium chloride (Crystal 
Violet). 
Crystal violet was made up using the following, 0.2% crystal violet powder in 100ml 2% 
ethanol. 
2.1.1.4 Dulbecco’s Modified Eagle Medium/Nutrient Mixture F-12 
working media (DMEM-F12). 
DMEM-F12 base media was made up using the following, 1 packet of Alpha medium and 
0.37% NaHCO3 in 1l MilliQ H2O. pH was the adjusted to between 7.1 and 7.3 with NaOH. 
This was then filtered in a cell culture laminar flow cabinet. 
This base media was supplemented with 5% (v/v) FBS, PenStrep antibiotics at a 
concentration of 100units/ml penicillin and 100µg/ml streptomycin, 2mM glutaMAX™ and 
2µg/ml Fungizone®. 
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2.1.1.5 Minimum Essential Medium working media (MEM). 
MEM base media was made up using the following, 1 packet of Alpha medium and 0.22% 
NaHCO3 in 1l MilliQ H2O. pH was the adjusted to between 7.1 and 7.3 with NaOH. This was 
then filtered in a cell culture laminar flow cabinet. 
This base media was supplemented with 5% (v/v) FBS, PenStrep antibiotics at a 
concentration of 100units/ml penicillin and 100µg/ml streptomycin, 2mM glutaMAX™ and 
2µg/ml Fungizone®. 
2.1.1.6 Tris-buffered Saline Solution (TBS). 
TBS was made up containing the following, 10ml 2M Tris-HCl (pH 7.5), 0.82% NaCl and 1l 
MilliQ H2O. 
TBS-T was made by adding 0.1% (v/v) Tween-20 to TBS. 
2.1.1.7 5x Sample Buffer. 
5x sample buffer was made up by using the following, 0.6ml 1M Tris-HCl pH 6.8, 5ml 50% 
glycerol, 2ml 10% SDS, 2ml 1% bromophenol blue and 0.4ml d.H2O. 
2.1.1.8 Radio-ImmunoPrecipitation Assay (RIPA) Lysis Buffer. 
RIPA lysis buffer was made up using the following, 20 pierce protease inhibitor cocktail 
tablets dissolved in 250ml RIPA buffer. 
2.1.1.9 Blocking buffer for immunofluorescence. 
Blocking buffer was made up containing the following, 4% BSA in PBS. 
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2.1.2 Potential Anti-carcinogenic Drugs. 
2.1.2.1 Resveratrol. 
Resveratrol was made up containing the following, 2mM resveratrol in 50% (v/v) DMSO 
and 50% (v/v) PBS. 
2.1.2.2 Acetyl Resveratrol. 
Acetyl Resveratrol was made up containing the following, 2mM Acetyl-resveratrol in 50% 
(v/v) DMSO and 50% (v/v) PBS. 
2.1.2.3 Epigallocatechin-3-gallate (EGCG). 
EGCG was made up containing the following, 1mM Epigallocatechin-3-gallate in working 
media (either DMEM-F12 or MEM). 
2.1.2.4 NF-kB inhibitor. 
NF-kB inhibitor was made up containing the following, 2mM Bay 11-7085 in 100% DMSO. 
2.1.3  Enzyme-Linked ImmunoSorbent Assay (ELISA) solutions 
and buffers. 
2.1.3.1 Washing Buffer. 
Wash buffer was made up containing the following, 0.05% Tween-20 in 1x PBS. 
2.1.3.2 VEGF Reagent Diluent. 
VEGF reagent diluent was made up containing the following, 1% BSA in 1x PBS. 
2.1.3.3 IL-8 Reagent Diluent. 
IL-8 reagent diluent was made up containing the following, 0.1% BSA, and 0.05% Tween-20 
in TBS. 
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2.1.3.4 IL-8 Blocking Buffer. 
IL-8 blocking buffer was made up containing the following, 1% BSA, 0.05%NaN3 in 1x PBS. 
2.1.4  Western Blot Solutions and Buffers. 
2.1.4.1 2M Tris-HCl (pH 8.8). 
2M Tris-HCl was made up containing the following, 24.2% Tris base, concentrated HCl to 
pH and MilliQ H2O to make total volume 100ml. 
2.1.4.2 1M Tris-HCl (pH 6.8). 
1M Tris-HCl was made up containing the following, 12.1% Tris base, concentrated HCl to 
pH and MilliQ H2O to make total volume 100ml. 
2.1.4.3  Solution B. 
Solution B was made up using the following, 75ml 2M Tris-HCl (pH 8.8), 4ml 10% SDS in 
d.H2O and 21ml MilliQ H2O. 
2.1.4.4  Solution C. 
Solution C was made up using the following, 50ml 1M Tris-HCl (pH 6.8). 4ml 10% SDS in 
d.H2O and 46ml MilliQ H2O. 
2.1.4.5 SDS-PAGE Separating Gel (10%). 
SDS-PAGE separating gel was made up using the following, 2.8ml d.H2O, 1.25ml solution B, 
1.66ml solution A (30% (w/v) acrylamide), 25µl 10% (w/v) (NH4)2S2O8 and 2.5µl TEMED. 
2.1.4.6 SDS-PAGE Stacking Gel (7%). 
SDS-PAGE stacking gel was made up using the following, 1ml d.H2O, 0.5ml solution C, 0.5ml 
solution A (30% w/v) acrylamide), 20µl 10% (w/v) (NH4)2S2O8 and 2.5µl TEMED. 
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2.1.4.7 Electrophoresis Buffer. 
Electrophoresis buffer was made up containing the following, 0.3% Tris, 1.4% glycine, 0.1% 
SDS and MilliQ H2O to make 1l. 
2.1.4.8 Transfer Buffer. 
Transfer buffer was made up using the following, 0.19% Tris, 0.9% glycine dissolved in 2l 
MilliQ H2O. 
2.1.4.9 Blocking Solutions. 
Blocking solutions were made up containing the following, either 5% (w/v) skim milk or 2% 
(w/v) BSA in TBS-T. 
2.1.4.10 Antibody Solutions. 
Antibody solutions were made up containing the following, either 2.5% (w/v) skim milk or 
1% (w/v) BSA in TBS-T. 
 
2.2 Methods. 
2.2.1  Cell Cultures. 
The well-established human cancer cell lines ovarian adenocarcinoma OVCAR-5 and SKOV-
3, were kindly provided by co-supervisor Dr. Chitcholtan (Department of Obstetrics and 
Gynaecology, University of Otago, Christchurch). OVCAR-5 was maintained in DMEM-F12 
working media and SKOV-3 was maintained in MEM working media. 
Both cell lines were maintained continuously in 50ml culture flasks containing the relevant 
working media in a humidified 5% CO2 incubator at 37°C. All subculturing procedures and 
experimental set ups were carried out under sterile conditions in a cell culture laminar flow 
cabinet. The media was replaced with fresh working media every two days until the cells 
were almost confluent, as assessed using a light microscope. At this stage, cells were sub-
cultured. To sub-culture, the media was discarded, the flask was then rinsed with sterile 1x 
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PBS and 5ml of sterile 1x Trypsin-EDTA was added. Flasks were then incubated for 15-25 
minutes until most cells no longer adhered to the bottom of the flask. Cells were then 
transferred into a 15ml tube and centrifuged at 1500rpm for 5 minutes, after which the 
supernatant was discarded. The cell pellet was then resuspended in the appropriate 
working media. A sample of the cell suspension was then taken and diluted in half with 1x 
PBS and a cell count was made using a haemocytometer. Approximately 300µl of the cell 
suspension was added to a new culture flask with fresh working media for cell line 
maintenance. 
2.2.1.1 Experimental 3D Spheroid/Clusters Cell Cultures. 
The following procedure was performed prior to sub-culturing cells in 12 well plates for 
each experiment. 0.5ml of 2.4% (w/v) poly-HEMA dissolved in 95% ethanol at 70°C was 
added to each well, the plates were then transferred to an orbital shaker set at 50rpm at a 
temperature of 37°C and left overnight with the lid slightly ajar to enable drying and 
setting of the polyHEMA. The plates were then removed and left at room temperature for 
24 hours to harden, the coated plates were then ready to use. Before adding cells the 
coated plates were washed with 1x PBS.  
For each experiment the average cell count that was obtained during sub-culturing was 
used to calculate the volume of cell suspension required for 1x105 cells per well. This 
volume was then added to each well in the coated 12 well plates and relevant working 
media was added to make a total volume of 1ml per well. The spheroids were grown for 6 
days before treatment and media in each well was replaced with fresh working media 
every two days. 
2.2.1.2 Drug Treatment. 
After 6 days of culturing, the spheroids/clusters were singly treated with resveratrol, acetyl 
resveratrol, EGCG or NF-kB inhibitor at one of three concentrations (10µM, 20µM and 
30µM). For the control, DMSO was added at a volume equal to that of the drug used in the 
highest concentration treatment. For the combination experiments 10µM of resveratrol 
and 10µM EGCG were combined and 20µM of each used singly. In each experiment, there 
were three replicate wells for each treatment. Plates were kept in the incubator and 
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spheroids were treated for either 2, 4 or 6 days, with fresh media and drugs administered 
every 2 days. 
2.2.2 Alamar Blue Assay. 
Cellular metabolism was assessed after drug treatment by the addition of Alamar Blue. 
Alamar Blue (resazurin) is a colourimetric REDOX indicator that is irreversibly reduced to 
the pink coloured compound resorufin in the presence of respiring cells. 0.5ml of the 
media was removed and discarded from each well before 50µl of Alamar Blue was added 
to each well. Plates were then incubated at 37°C for 4 hours before a sample was taken 
from each well and loaded onto a 96 well plate. The colour change was measured by 
absorbance at 570nm and 600nm using a microplate reader (SpectraMax® M5, Molecular 
Devices). The difference between the absorbances was used as a measure of metabolic 
activity. 
2.2.3 Crystal Violet Assay. 
Following the Alamar Blue Assay, cell numbers were indirectly determined by staining 
cellular DNA purple with crystal violet. The light absorbance of crystal violet at a 
wavelength of 570nm enables quantification of the amount of DNA in a sample which is 
taken as being proportional to the total cell number. 1ml 1x PBS was added to each well to 
rinse out the Alamar Blue. Spheroids were then transferred to 5ml tubes, 3ml 1x PBS 
added and then centrifuged at 2500rpm for 5 minutes. The supernatant was discarded and 
300µl of 10x non sterile trypsin-EDTA was added to separate the cells. After incubation for 
30 minutes at 37°C, cells were pelleted by centrifugation at 2500rpm for 5 minutes and the 
supernatant discarded. 50µl of crystal violet was added and incubated at room 
temperature for 15 minutes. The cells were then washed with MiliQ H2O to remove any 
non DNA-bound dye and centrifuged at 3500rpm. The wash was repeated three times, 
then the cells were lysed with 2% (w/v) SDS in distilled H2O. The cell solutions were then 
loaded onto a 96-well plate and the optical density at 560nm measured using the 
microplate reader. 
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2.2.4 VEGF and IL-8 ELISA. 
Treatment media of the spheroids/clusters were collected and centrifuged at 3000rpm for 
5 minutes. The supernatant was aspirated, and stored at -20°C for the analysis of VEGF and 
IL-8 secretion. For the sandwich ELISAs, the protocol from the manufacturer was strictly 
adhered to and is as follows. Capture antibody diluted in 1x PBS was added to each well 
being used (as calculated previously) in a 96-well ELISA plate (Nunc, Thermo scientific, 
Illinois, USA) and incubated at room temperature overnight. The wells were then washed 
four times using the wash buffer and blocking buffer (Reagent diluent for VEGF) was 
added. After incubation at room temperature for 1 hour the wells were again washed four 
times, then two sets of standards and 2x diluted (with 1x PBS) samples were added. These 
were incubated at room temperature for two hours. The plate was washed four times then 
detection antibody diluted with reagent diluent was added and incubated for another two 
hours at room temperature. After washing four times streptavidin-HRP diluted with 
reagent diluent was added and the plate was then incubated at room temperature in the 
dark for 20 minutes. The wells were again washed four times and ultra TMB-ELISA added. 
After 7-10 minutes 2NH2SO4 was added and the absorbance at 450nm was measured using 
the microplate reader. 
2.2.5 BCA Protein Assay. 
BCA protein assays were carried out using an assay kit (Thermo Scientific, Illinois, USA) in 
order to determine the total protein in the pellets. This was conducted to normalise the 
protein concentrations in each sample for ELISA and Western Blotting. Pellets were lysed 
by adding 200µl of ice-cold RIPA lysis buffer to each sample and incubating for 30 minutes 
on ice. 25µl of each unknown sample was then loaded onto a 96-well plate along with two 
sets of standards. To each well 200µl of the working reagent (50:1, Reagent A:B) was 
added, the contents of the wells on the plate were mixed on an orbital shaker then 
incubated at 37°C for 30 minutes. Absorbance was measured at 562nm using the 
microplate reader. 
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2.2.6 Western Blotting. 
After the BCA protein assay 20µl of 5x sample buffer was added to each sample. The 
samples were vortexed, heated at 99°C for 10 minutes, put on ice for 10minutes followed 
by centrifugation for 5 minutes at 10,000rpm. Gels were prepared with the 10% SDS-PAGE 
separating gel and the 7% stacking gel. Samples were loaded onto gels at a volume, 
determined by the total protein concentration, required to load 10µg of protein per 
sample. MagicMark™ Western Protein Standard and Precision Plus Protein™ standard 
were used as SDS-PAGE markers. The SDS-PAGE was run for approximately 120 minutes at 
120 volts using Electrophoresis buffer. Following SDS-PAGE the separated proteins were 
transferred onto polyvinyl difluoride (PVDF) membranes (BIO-RAD, Hercules, USA), running 
at 100 volts for 60 minutes in cold Transfer buffer. Membranes were then put in the 
appropriate blocking solution for 60 minutes. The blocking solution was discarded, 
membranes washed with MilliQ water for 5 minutes, then diluted primary antibody added 
and incubated overnight at 4°C. The primary antibody was then discarded and membranes 
were washed for 10 minutes with TBS-T on an orbital shaker. This wash step was repeated 
four times with fresh TBS-T each time before incubation for 90 minutes at room 
temperature with the appropriate diluted secondary antibody. The membranes were again 
washed four times with TBS-T and then developed using a chemiluminescence detection 
kit (Amersham™ ECL™ Prime Western Blotting Detection Reagent Kit, GE Healthcare). 
Protein bands were imaged and densitometry analysis performed using Alliance 4.7, Uvitec 
software (Cambridge, UK).  
2.2.7 Frozen Sectioning and Immunofluorescence. 
2.2.7.1 Sample preparation. 
Spheroids were harvested in 1.5ml eppendorf tubes after growing and treating as 
described above. After centrifugation at 2000rpm for 5 minutes media was removed and 
discarded. 1ml of an ice cold 50/50 methanol acetone solution was added to each tube and 
tubes were kept at -20°C. 
 
37 
 
2.2.7.1.1 SKOV-3  
Samples were centrifuged at 2500rpm for 5 minutes and the supernatant removed and 
discarded. Pellets were then washed with 1ml of PBS, centrifuged at 2500rpm and the 
supernatant discarded. This wash step was repeated twice, before 200µl of aniline blue 
was added to each tube and incubated at room temperature for 20 minutes. Tubes were 
again centrifuged at 2500rpm, the supernatant was discarded and pellets were washed as 
described above a further three times. Samples were then prepared for sectioning as the 
spheroids of SKOV-3 are too thick to visualise with the microscope without sectioning. 
Approximately 0.5ml CryO-Z-T was added to each tube and pre-labelled plastic rectangle 
plates evenly covered with CryO-Z-T. The stained spheroids with the CryO-Z-T were then 
pipetted onto the covered plate and any large bubbles that formed were removed. Plates 
were frozen overnight at -80°C and then stored at -20°C. 
2.2.7.1.2 OVCAR-5 
Samples were centrifuged at 2500rpm for 5 minutes and the methanol/acetone 
supernatant discarded. The pellet was then washed with 1ml of 1x PBS, centrifuged at 
2500rpm for another 5 minutes and the supernatant again discarded. The wash was 
repeated once more and then 200ml of 1x PBS added to each sample. No sectioning was 
required for OVCAR-5 as this cell line formed small clusters that were easily visualised 
under the epifluorescent microscope. 
2.2.7.2  Slide preparation. 
2.2.7.2.1 SKOV-3. 
Superfrost plus microscope slides (Menzel-glaser, Germany) were first appropriately 
labelled in pencil. A chuck and block were placed in dry ice to freeze. CryO-Z-T was then 
utilised to mount the frozen sample onto the chuck. Samples were kept on dry ice when 
not in use. The mounted sample was loaded into a cryostat and sectioned. Two slices 7µM 
thick were placed on each slide and six slices per sample were collected. Slides were stored 
at -20°C. 
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2.2.7.2.2 OVCAR-5. 
Firstly Polysine microscope slides (Thermofisher, NZ) were labelled in pencil and a 20mm 
silicone isolator (Invitrogen, NZ) adhered. The 200ml samples were then loaded onto the 
appropriate slide and left to dry at 37°C. Once dry the isolator was removed. 
2.2.7.3 Sample Staining. 
SKOV-3 and OVCAR-5. 
A super pap pen was utilised to enclose each sample. 200µl of blocking buffer was then 
added to each sample and incubated at room temperature for 1 hour. The slides were then 
washed for 10 minutes with PBS before primary antibodies were administered at a dilution 
factor of 1:200 in PBS with 2% BSA. These were incubated overnight at 4°C. 
Slides were then washed twice for 10 minutes with PBS and secondary antibody (goat anti-
rabbit IgG conjugated with Atto 594nm) added at a 1:1000 dilution with 2% BSA in PBS. 
After one hour incubation at 37°C, the samples were then stained with 10µg/ml Hoechst 
stain for 20 minutes. The slides were then washed three times with PBS + 0.1% Tween-20, 
2-3 drops anti-fading solution (2g/l p-phenylenediamine in 80% glycerol) applied and 
covered with a coverslip. Slides were observed and imaged with an epifluorescence 
microscope (AxioVision 4.5. Apotome software, Carl Zeiss, Oberkochen, Germany). 
2.2.8 Statistical Analysis. 
Statistical analyses were performed using GraphPad Prism® software (La Jolla, CA, USA). 
Experimental results were assessed for significance using an unpaired t-test (using P < 0.05 
as a measure of statistical significance). 
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Chapter 3.  
Effects of Dietary Polyphenols on Cellular 
Metabolism and Growth of Ovarian 
Spheroids/Clusters. 
3.1 Introduction. 
3.1.1 Cell Division in Normal and Cancerous Cells. 
 
Cell division is how all somatic animal cells including cancer proliferate. The cell cycle 
begins when the cell is produced from the mother cell and lasts until the cell undergoes its 
own division into two daughter cells. The cell cycle can be divided into two stages, 
interphase and mitosis. A majority of the cell cycle is interphase, this is a period for DNA 
replication and growth, which can be further divided into 3 phases, G1 (first growth phase), 
S (synthesis) and G2 (second growth phase). DNA is replicated during S phase whilst 
proteins and other cellular components are produced during the other two phases (Alberts 
et al., 2007). The mitotic phase is the stage during which the cell divides into two identical 
daughter cells and accounts for about 20% of the cell cycle. In general the nuclear 
envelope breaks down, the replicated chromosomes are separated and the two identical 
sets of chromosomes are enveloped by their own nucleus. The cell then divides into two 
daughter cells containing roughly equal shares of organelles and cytoplasm (Alberts et al., 
2007). Normal cells will only undergo mitotic division a set number of times before ceasing 
being able to reproduce this is known as the hayflick limit (Shay and Wright, 2000). Cancer 
cells however, do not become senescent and are able to divide indefinitely. In normal cells, 
the cell cycle is tightly regulated by cell cycle regulators such as cyclins, cyclin-dependent 
kinases (CDKs) and checkpoint proteins. Normal cells respond to extracellular signals 
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through the regulators at G1 phase and exit from the cell cycle, entering G0 (resting) phase, 
cells in G0 make up a major part of the human body’s non-cycling cells (Vermeulen et al., 
2003). In contrast, cancer cells have mutations usually in either proto-oncogenes which are 
often involved in signal transduction of mitogenic signals, or tumour suppressor genes. 
Inactivation of these suppressor genes disrupts proteins that are usually responsible for 
inhibiting cell cycle progression. Thus, cancer cells are unable to exit the cell cycle and 
continuously proliferate (Sherr, 1996).  
 
3.1.2 Apoptosis in normal and cancerous cells. 
 
In animal tissue homeostasis is maintained through the eradication of damaged or 
superfluous cells by cell death or apoptosis. Apoptosis morphology is characterized by 
chromatin condensation, cytoplasmic shrinkage, nuclear fragmentation, membrane 
blebbing, DNA fragmentation, and the formation of apoptotic bodies within the 
cytoplasmic content. During apoptosis, caspases which are cysteine-aspartic proteases, 
cleave vital cellular substrates and are essential to programmed cell death (Lowe and Lin, 
2000).  
The activation of apoptosis is achieved by either extrinsic or intrinsic signals. Extrinsic 
signals bind to ‘death receptors’ which trigger their downstream caspases. Intrinsic signals 
are mediated by the mitochondria and induced by things such as DNA damage or viral 
infection (Piotrowska et al., 2012). Destabilized mitochondria release cytochrome-c which 
subsequently causes the oligomerization of the apoptotic protease activating factor 1 
(Apaf-1) and the formation of apoptosomes. The apoptosomes then activate caspases and 
induce proteolysis of the cell (Reimann and Schmitt, 2007). The more common mutations 
in cancers that enable them to elude cell death occur in the bcl-2 and p53 genes (Lowe and 
Lin, 2000). The contribution of both the intrinsic and extrinsic pathways to cancer cell 
apoptosis depend on differences between cancer cell types and the cytotoxic agent utilised 
(Piotrowska et al., 2012). 
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3.1.3 Natural food compounds and cancerous cell growth. 
 
EGCG was one of the first natural food compounds to be recognised for its anti-
proliferative effect on cancers in the late 80’s (Ahmad and Mukhtar, 1999). It has been 
demonstrated that EGCG affects several biological pathways in cancer cell proliferation, for 
example it supresses aberrant CDKs, cyclins and Ras –products of which regulate cell 
growth (Singh et al., 2011). EGCG has also been shown to be able to upregulate apoptotic 
caspases and modulate anti-apoptotic proteins such as Bcl-2 and survivin, as well as many 
others. 
Resveratrol’s adverse effect on cancer growth was first observed in 1997 (Shukla and 
Singh, 2011). Since then there have been many studies into the mechanisms of 
resveratrol’s anti-tumorous effects (Baur and Sinclair, 2006, Athar et al., 2009, Cui et al., 
2010, Gatouillat et al., 2010). Thus far, it has been revealed that resveratrol is also active in 
several cell growth and apoptotic pathways in cancer cells and affects the expression of 
cyclins, PTEN (a tumour suppressor), caspases and CDKs to name a few (Shukla and Singh, 
2011). Unlike EGCG and resveratrol the effects of acetyl resveratrol on cancer appears to 
have not yet been investigated. 
 
3.1.4 Aims of Chapter 3. 
In this chapter the overall aim is to investigate the effect that resveratrol, acetyl resveratrol 
and EGCG have on the cellular metabolism and growth of ovarian cancer 
spheroids/clusters utilising the well-established ovarian cell lines SKOV-3 and OVCAR-5.   
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3.2 Methods and Materials. 
Experimental 3D spheroid cell cultures -See Chapter 2 for full method and materials. 
Alamar Blue Assay -See Chapter 2 for full method and materials. 
Crystal Violet Assay -See Chapter 2 for full method and materials. 
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3.3 Results. 
3.3.1 Two Day Treatment Effects on Cellular Metabolism and      
Proliferation. 
For resveratrol there was no change in cellular metabolism in both the OVCAR-5 and SKOV-
3 cell lines after 2 days of treatment (Fig 3.1 a, b). Similar results were also observed in 
acetyl resveratrol treated cells (Fig. 3.2 a, b). However, after two days of treatment with 
30µM EGCG (Fig. 3.3 b) OVCAR-5 responded with a small increase and there is also a non-
significant increase for the same cell line in the combination experiments (Fig. 3.3 b).  
Cell growth for SKOV-3 was decreased after 2 days treatment with 20µM and 30µM 
resveratrol (Fig. 3.1 c) by 13% and 19%, respectively. The acetyl resveratrol and EGCG 
treatments for 2 days did not affect either cell line (Fig. 3.2 c, d Fig. 3.3 c, d). Unexpectedly, 
the SKOV-3 cell growth increased by 23% (p= 0.038, t-test, n= 3) when treated with the 
combination of resveratrol and EGCG (Fig. 3.4 d).  
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Figure 3.1. Relative cellular metabolism (as determined by Alamar Blue assay) and growth 
activity (as determined by a crystal violet assay) of SKOV-3 (a, c) and OVCAR-5 (b, d) 
spheroids/clusters treated with various concentrations of resveratrol for 2 days. Data are 
from four independent experiments carried out in triplicate ± SEM. * denotes statistical 
significance (t-test, P < 0.05) relative to the control. 
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Figure 3.2. Relative cellular metabolism (as determined by Alamar Blue assay) and growth 
activity (as determined by a crystal violet assay) of SKOV-3 (a, c) and OVCAR-5 (b, d) 
spheroids/clusters treated with various concentrations of acetyl resveratrol for 2 days. 
Data are from four independent experiments carried out in triplicate ± SEM. * denotes 
statistical significance (t-test, P < 0.05) relative to the control. 
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Figure 3.3. Relative cellular metabolism (as determined by Alamar Blue assay) and growth 
activity (as determined by a crystal violet assay) of SKOV-3 (a, c) and OVCAR-5 (b, d) 
spheroids/clusters treated with various concentrations of EGCG for 2 days. Data are from 
four independent experiments carried out in triplicate ± SEM. * denotes statistical 
significance (t-test, P < 0.05) relative to the control. 
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Figure 3.4. Relative cellular metabolism (as determined by Alamar Blue assay) and growth 
activity (as determined by a crystal violet assay) of SKOV-3 (a, c) and OVCAR-5 (b, d) 
spheroids/clusters treated with 20µM resveratrol, 20µM EGCG or 10µM resveratrol + 
10µM EGCG (combination) for 2 days. Data are from three independent experiments 
carried out in triplicate ± SEM. * denotes statistical significance (t-test, P < 0.05) relative to 
the control. 
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3.3.2 Four day treatment effects on Cellular Metabolism and 
Proliferation. 
After four days of treatment with 10 and 30µM resveratrol cell metabolism of SKOV-3 was 
decreased by 22% (Fig. 3.5 a). About 14% growth reduction was also observed in SKOV-3 
after four days of 30µM resveratrol treatment (Fig. 3.5 c). 
Acetyl resveratrol did not affect cellular metabolism or cell growth in either cell line (Fig. 
3.6 a, b, c, d) after four days of treatment. EGCG treatment at 10µM slightly increased 
metabolism of OVCAR-5 (Fig. 3.7) and 30µM EGCG slightly decreased SKOV-3 growth 
activity (Fig. 3.7 c). 
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Figure 3.5. Relative cellular metabolism (as determined by Alamar Blue assay) and growth 
activity (as determined by a crystal violet assay) of SKOV-3 (a, c) and OVCAR-5 (b, d) 
spheroids/clusters treated with various concentrations of resveratrol for 4 days. Data are 
from four independent experiments carried out in triplicate ± SEM. * denotes statistical 
significance (t-test, P < 0.05) relative to the control. 
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Figure 3.6. Relative cellular metabolism (as determined by Alamar Blue assay) and growth 
activity (as determined by a crystal violet assay) of SKOV-3 (a, c) and OVCAR-5 (b, d) 
spheroids/clusters treated with various concentrations of acetyl resveratrol for 4 days. 
Data are from four independent experiments carried out in triplicate ± SEM. * denotes 
statistical significance (t-test, P < 0.05) relative to the control. 
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Figure 3.7. Relative cellular metabolism (as determined by Alamar Blue assay) and growth 
activity (as determined by a crystal violet assay) of SKOV-3 (a, c) and OVCAR-5 (b, d) 
spheroids/clusters treated with various concentrations of EGCG for 4 days. Data are from 
four independent experiments carried out in triplicate ± SEM. * denotes statistical 
significance (t-test, P < 0.05) relative to the control. 
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3.3.3 Six day treatment effects on Cellular Metabolism and 
Proliferation. 
The SKOV-3 cell line was strongly affected after 6 days of treatment with resveratrol and 
acetyl resveratrol. Cellular metabolism was decreased by 36% and 39% after 20µM and 
30µM resveratrol treatment respectively (Fig. 3.8 a). Cell growth reduced across all three 
doses of resveratrol (Fig. 3.8 c). Cell growth also decreased with all three treatment 
strengths of acetyl resveratrol (Fig. 3.9 c). In the combination experiments there is no 
significant difference between the single treatments of resveratrol or EGCG and the 
treatment with a combination of the two (Fig. 3.11 a, c). 
The cellular metabolism of OVCAR-5 and cell growth were unaffected by 6 day treatment 
with resveratrol, acetyl resveratrol and the combination of 10µM EGCG with 10µM 
resveratrol (Fig. 3.8 b, d Fig. 3.9 b, d Fig. 3.11 b, d). Six days of treatment with EGCG did not 
affect either cell lines metabolic or growth activity (Fig. 3.10 a, b, c, d). 
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Figure 3.8. Relative cellular metabolism (as determined by Alamar Blue assay) and growth 
activity (as determined by a crystal violet assay) of SKOV-3 (a, c) and OVCAR-5 (b, d) 
spheroids/clusters treated with various concentrations of resveratrol for 6 days. Data are 
from four independent experiments carried out in triplicate ± SEM. * denotes statistical 
significance (t-test, P < 0.05) relative to the control. 
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Figure 3.9. Relative cellular metabolism (as determined by Alamar Blue assay) and growth 
activity (as determined by a crystal violet assay) of SKOV-3 (a, c) and OVCAR-5 (b, d) 
spheroids/clusters treated with various concentrations of acetyl resveratrol for 6 days. 
Data are from four independent experiments carried out in triplicate ± SEM. * denotes 
statistical significance (t-test, P < 0.05) relative to the control. 
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Figure 3.10. Relative cellular metabolism (as determined by Alamar Blue assay) and growth 
activity (as determined by a crystal violet assay) of SKOV-3 (a, c) and OVCAR-5 (b, d) 
spheroids/clusters treated with various concentrations of EGCG for 6 days. Data are from 
four independent experiments carried out in triplicate ± SEM. * denotes statistical 
significance (t-test, P < 0.05) relative to the control. 
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Figure 3.11. Relative cellular metabolism (as determined by Alamar Blue assay) and growth 
activity (as determined by a crystal violet assay) of SKOV-3 (a, c) and OVCAR-5 (b, d) 
spheroids/clusters treated with 20µM resveratrol, 20µM EGCG or 10µM resveratrol + 
10µM EGCG (combination) for 6 days. Data are from four independent experiments carried 
out in triplicate ± SEM. * denotes statistical significance (t-test, P < 0.05) relative to the 
control. 
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3.3.4 Six Day Resveratrol Treatment effects on Spheroid/cluster 
morphology. 
There were obvious morphological differences between the 3D cultures of the two cell 
lines. The SKOV-3 spheroids/clusters were over 10 fold larger than the OVCAR-5 ones (Fig. 
3.12, Fig. 3.13). The OVCAR-5 spheroids/clusters were also quite uniform in size whereas 
the SKOV-3 spheroids/clusters were very irregular in shape. Resveratrol was the only 
treatment that had any obvious effect on the morphology of either cell line (other 
treatment effects not shown). The size and density of SKOV-3 spheroids/clusters noticeably 
decreased after treatment with 20 and 30 µM of resveratrol for 6 days compared to the 
control (Fig. 3.12 a, c, d). Although the OVCAR-5 spheroids/clusters were more dispersed 
after the 20 and 30 µM resveratrol treatments compared to the control (Fig. 3.13 a, c, d) 
there was no noticeable effect on the size or density of the spheroids/clusters. 
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Figure 3.12. Morphology of SKOV-3 spheroids/clusters after 6 days treatment with 
resveratrol.  (a) Control (b) 10µM resveratrol (c) 20µM resveratrol and (d) 30µM 
resveratrol. The morphology of the spheroids/clusters observably changed after treatment 
with 20 and 30µM resveratrol. 
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Figure 3.13. Morphology of OVCAR-5 spheroids/clusters after 6 days treatment with 
resveratrol. (a) Control (b) 10µM resveratrol (c) 20µM resveratrol and (d) 30µM 
resveratrol. The morphology of the spheroids/clusters did not observably change. 
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3.4 Discussion. 
Many of the ovarian cancer chemotherapeutical agents currently in use are also known to 
be toxic to normal cells. To address this, it is highly important to utilise drugs that 
specifically induce cancer cell death whilst leaving healthy cells untouched. To this end, 
there are many natural food derivatives under investigation for their purported anti-cancer 
properties.  
3.4.1 Resveratrol. 
One such natural compound being investigated for potential anti-carcinogenic properties is 
the stilbenoid resveratrol. The most readily available food source with the highest 
concentration of resveratrol (2-40µM) is red wine, as it is present in the skin of red grapes 
(Kraft et al., 2009). Resveratrol has proven to be effective in decreasing cell proliferation in 
other epithelial-derived cancers such as skin, breast, prostate and lung (Stakleff et al., 
2012). However, the results of those studies face difficulties when attempting to 
extrapolate to human in vivo conditions as they utilised either monolayer cell cultures or 
animal models. 
Ovarian cancer’s response to resveratrol is evidentially cell line dependant as OVCAR-5 is 
unaffected by the treatment whereas SKOV-3 displays a reduction in cellular metabolism 
and growth. This cell line dependency has also been observed in monolayer cultures of 
ovarian cancer (Cao et al., 2004, Lee et al., 2009) but to the best of my knowledge has not 
been demonstrated in a 3D culture. 
The response of SKOV-3 is also time and dose dependant. The concentrations utilised in 
this study were chosen to fall within the amount of resveratrol found in red wine and what 
potentially may be present in vivo after imbibing a glass or two. After just 2 days treatment 
cell growth somewhat declined with the stronger treatments. It might seem unusual that 
cell proliferation decreased whilst metabolism did not. It is suggested that this is due to the 
size of the SKOV-3 spheroids/clusters. These spheroids/clusters are quite large therefore 
the surface area exposed to the alamar blue dye would not significantly change even 
though the cell number has decreased. Thus, the metabolic rate would appear unchanged 
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despite the loss of cells. After four days treatment with 30µM resveratrol metabolism and 
growth are reduced, then after six days metabolic rates have further declined with the 
stronger treatments (20 and 30µM) and cell growth is reduced with all three.  
This is once again a novel outcome in the 3D structure and is also in accordance with 
previous monolayer studies, where SKOV-3’s cell growth declined with stronger 
concentrations after one or two days and with lower concentrations after a longer time 
period (Raj et al. 2008; Lee et al., 2009). At four days of treatment with 10µM there is a 
reduction of metabolism but not proliferation, this is most likely an anomaly as it is not 
apparent at the higher concentration (20µM) with the same treatment time. Again one 
experiment had much lower results than the others, the P value is high and given a further 
replicate it is possible that the decrease would become non-significant. 
The morphology of the spheroids/clusters after six days treatment with 20 and 30µM 
resveratrol is also affected with their size being dramatically reduced and their density also 
being observably reduced. These observations support the cell metabolism and growth 
results. 
3.4.2 Acetyl resveratrol. 
There is evidence however, that resveratrol has low bioavailability and the concentrations 
that reach the peritoneal cavity may be in the nanomolar range (Walle, 2011). One 
approach to address this is to utilise resveratrol analogues (Colin et al., 2009). Acetyl 
resveratrol is one such naturally occurring analogue where the hydroxyl groups of 
resveratrol are acetylated, this acetylation is purported to improve metabolic stability in 
humans as it does so in rats (Liang et al., 2013). Acetyl resveratrol is shown here to again 
be a cell line specific drug with OVCAR-5 being resistant and also time and dose dependant 
as there was no change in either metabolism or growth of SKOV-3 until the sixth day when 
only proliferation declined with all three drug concentrations. As above the reduction in 
growth and not cellular metabolism is attributed to the relatively large size of the 
spheroids/clusters formed. 
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3.4.3 EGCG. 
EGCG a green tea constituent is another food derivative that is under investigation. In this 
study, overall EGCG demonstrated a lack of either time or dose dependent inhibition of the 
growth or metabolism of spheroids/clusters of either ovarian cancer cell line. In fact, 
OVCAR-5 appears to have a slightly positive response to the treatments; however this is 
not apparent as a dose or time dependant effect. SKOV-3 displayed a reduction in growth 
after four days treatment but the fact that the six day treatment did not display the same 
effect suggests that this may be an anomaly attributed to one experiment with particularly 
low readings and the P value is close to non-significant. Given a further replicate 
experiment, it is possible that the decrease would become non-significant.  Although there 
is a plethora of studies revealing that EGCG is effective in reducing cell proliferation and or 
tumour size in cancers such as cervical, oesophagus, skin, and lung (Lu et al., 2002, Ahn et 
al., 2003, Lu et al., 2006) many of these use animal models and the differences between 
animals and humans in regards to metabolism make it difficult to extrapolate the results 
(Zhang et al., 2012). Huh et al., 2004 found that cell proliferation of ovarian cancer is 
supressed by EGCG; however the study was performed on 2-dimensional monolayers of 
cells in vitro, it is probable that EGCG is ineffectual in this study due to inadequate 
penetration of the clusters. The concentrations examined in this study are also much lower 
than many previous studies including Huh et al., 2004, who used 25-100µM EGCG to treat 
SKOV-3. The typical cup of green tea only contains 50-75mg of EGCG (Zhang et al., 2006) 
and of this circa 0.6µM is detected in human blood after consumption (Ahn et al., 2003), 
thus concentrations were chosen to better reflect amounts that could be expected to be 
present in vivo. 
3.4.4 Resveratrol and EGCG combination. 
It was hypothesised that resveratrol and EGCG can work synergistically in the 3D model. As 
resveratrol was able to downregulate cellular metabolism and proliferation in a 3D 
structure whereas EGCG was only effective on a 2D structure then resveratrol could 
sensitize the cluster allowing EGCG penetration. Thus combination experiments were 
undertaken, however no synergistic effect was observed. 
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Chapter 4.  
Effects of Dietary Polyphenols on the Secretion of 
Angiogenic Proteins. 
4.1 Introduction. 
Data presented earlier in the thesis has shown that there is a reduction in cellular 
metabolism and growth in response to resveratrol and acetyl resveratrol at concentrations 
of 20 and 30 µM after four and six days of treatment. This chapter investigates the 
secretion of the angiogenic proteins Vascular Endothelial Growth Factor (VEGF) and 
Interleukin 8 (IL-8) as two possible factors involved in the effects of resveratrol and acetyl 
resveratrol. 
4.1.1 Vascular Endothelial Growth Factor (VEGF). 
4.1.1.1 Background. 
VEGF is a homodimeric glycoprotein with a molecular weight of 45kDa; it plays a role in a 
diverse range of angiogenic activities. Angiogenesis is the physiological development of 
new blood vessels from pre-existing arteries, veins and lymphatic vessels. VEGF is a key 
regulator of angiogenesis during skeletal growth, embryogenesis and cyclical ovarian 
function (Ferrara et al., 2003). VEGF stimulates the proliferation and survival of vascular 
endothelial cells (Ferrara et al., 2003).  
4.1.1.2 VEGF and Cancer. 
For the development and growth of solid tumours, angiogenesis is of fundamental 
importance and as stated previously VEGF is essential to this process (Shimizu et al., 2010). 
Angiogenesis is significant in tumour progression as it supplies oxygen, nutrients, growth 
factors and hormones, basically, everything that a tumour needs to flourish (Hicklin and 
Ellis, 2005). VEGF has also been shown to mediate vessel permeability, this is also crucial in 
cancer development as this enables the metastasis of the malignant cells (Hicklin and Ellis, 
2005). The ‘switch’ to an angiogenic phenotype is thought to be a trademark of the 
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malignancy process and the overexpression of VEGF is related to advanced stages of the 
disease and a poor prognosis for patients in an assortment of cancers (Hicklin and Ellis, 
2005). There is also evidence that tumour cells express VEGF receptors, this expression has 
been suggested to produce an autocrine loop, which enables these cells to avert apoptosis 
when VEGF is present (Hicklin and Ellis, 2005).  
4.1.1.3 VEGF and Ovarian Cancer. 
It has been suggested that the ability of VEGF to induce vascular permeability is vital for 
the formation of malignant ascites in ovarian cancer (Mesiano et al., 1998). Overexpression 
of VEGF has been observed in ovarian cancer cell lines and has been linked to cell 
proliferation (Cao et al., 2004, Park et al., 2007). The expression level of VEGF in the ascites 
and primary tumours directly correlates with a poor prognosis (Yu et al., 2013). Together, 
these findings suggest a strong possibility that VEGF is important in tumour growth in 
ovarian cancer.  
4.1.2 Interleukin-8 (IL-8). 
4.1.2.1 Background. 
The pro-inflammatory chemokine IL-8 is a 10 kDa glycoprotein. It is induced by 
inflammatory stimuli and promotes a series of physiological responses that are needed for 
cell migration and phagocytosis (Hebert and Baker, 1993). IL-8 is primarily responsible for 
the chemoattraction and activation of neutrophils at sites of inflammation (Holmes et al., 
1991). It stimulates neutrophil degranulation and inhibits their adherence to activated 
endothelial cells (Holmes et al., 1991). 
4.1.2.2 IL-8 and Cancer.  
IL-8 is purported to be essential for tumour inflammation, angiogenesis and growth in 
many cancers (Sparmann and Bar-Sagi, 2004). Its overexpression has been identified in a 
variety of cancers including breast, colon, cervical, gastric and lung cancer (Xie, 2001). The 
identification of receptors of the chemokine on tumour cells has led to the suggestion that 
IL-8 can also form an autocrine loop and thus, sustain endothelial and cancer cell survival 
(Xie, 2001). The inhibition of IL-8 secretion resulting in decreased cell proliferation has 
been established in melanoma, cervical, pancreatic and colon cancers (Xie, 2001, 
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Sparmann and Bar-Sagi, 2004,). IL-8 signalling has also been shown to be inducible by drug 
treatment and result in resistance of chemotherapies in some cancers (Waugh and Wilson, 
2008).  
4.1.2.3 IL-8 and Ovarian Cancer. 
Overall, there have been relatively few investigations into the relationship between 
ovarian cancer and IL-8. However, there is evidence that in some ovarian cancer cell lines 
the expression level of IL-8 is correlated with the aggressiveness of the disease (Huang et 
al., 2000). Suppression of IL-8 secretion has also been linked to the attenuation of tumour 
growth and angiogenesis of ovarian cancer (Huang et al., 2000, Waugh and Wilson, 2008). 
These studies indicate that IL-8 may potentiate ovarian cancer cell growth and is a possible 
target of the natural drug treatments. 
4.1.3 Aims of chapter 4. 
This chapter aims to investigate whether VEGF and/or IL-8 secretion is attenuated by 
resveratrol, acetyl resveratrol or EGCG in the ovarian cancer cell lines SKOV-3 and OVCAR-
5.  
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4.2 Methods and Materials. 
Experimental 3D spheroid cell cultures -See Chapter 2 for full method and materials. 
VEGF and IL-8 ELISA -See Chapter 2 for full method and materials. 
BCA Protein Assay -See Chapter 2 for full method and materials. 
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4.3 Results. 
4.3.1 VEGF 
4.3.1.1 VEGF secretion in basal conditions. 
The concentration of VEGF present in cell media after two, four or six days of drug 
treatment was assessed using the human VEGF ELISA Kit. An 8 point standard curve was 
created and the amount of VEGF in each sample was found by comparing absorbance of 
the samples to the standard curve. The concentrations were then normalised by dividing 
the amount by the total protein of the sample obtained using the BSA protein assay. 
The secretion of VEGF was approximately four times higher from the SKOV-3 cell cultures 
than from OVCAR-5 cultures (Fig. 4.1, 4.2, 4.3, 4.4). The variation of base secretion for 
SKOV-3 was between 1.3 and 7.4 ng/ml/mg (Fig. 4.1 c Fig. 4.3 c). For OVCAR-5, the 
variation was from 0.4 to 1.1 ng/ml/mg (Fig. 4.1 b, f). 
4.3.1.2 Resveratrol Treatment Effects on Secreted VEGF Concentrations. 
The response to resveratrol treatment was cell line dependant with only SKOV-3 VEGF 
levels being affected significantly (Fig. 4.1). A time and dose dependency was also evident 
as after two days there was no significant effect, however after four and six days of 
treatment there was a trend of decreasing VEGF concentration with increasing dosage (Fig. 
4.1 a, c, e) and the highest concentration of resveratrol resulted in a 41 and 54% decline in 
four and six day VEGF concentrations respectively when compared to the control (Fig. 4.1 
c, e).  
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Figure 4.1. VEGF supernatant concentration (as determined by ELISA and expressed as 
ng/ml VEGF/mg total cell protein content) of SKOV-3 (a, c, e) and OVCAR-5 (b, d, f) 
spheroids/clusters treated with various concentrations of resveratrol for 2 days (a, b), 4 
days (c, d) or 6 days (e, f). Data are from four independent experiments carried out in 
triplicate ± SEM. * denotes statistical significance (t-test P<0.05) relative to the control. 
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4.2.1.3 Acetyl resveratrol Treatment Effects on Secreted VEGF 
Concentrations. 
SKOV-3 was again the cell line that showed a response to the treatment (Fig. 4.2). The 
effect was dose dependant with the strongest dose tested 30µM decreasing VEGF 
secretion by 49% after four days treatment (Fig. 4.2 c) and by 58% after 6 days treatment 
(Fig. 4.2 e). There was also a time dependant effect as the decrease was at its greatest 
after six days treatment, whilst there was no significant suppression after two days (Fig.4.2 
a, c, e). 
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Figure 4.2. VEGF supernatant concentration (as determined by ELISA and expressed as 
ng/ml VEGF/mg total cell protein content) of SKOV-3 (a, c, e) and OVCAR-5 (b, d, f) 
spheroids/clusters treated with various concentrations of acetyl resveratrol for 2 days (a, 
b), 4 days (c, d) or 6 days (e, f). Data are from three independent experiments carried out 
in triplicate ± SEM. * denotes statistical significance (t-test P<0.05) relative to the control. 
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4.2.1.4 EGCG Treatment Effects on Secreted VEGF Concentrations. 
There was no significant effect on VEGF secretion in either cell line by EGCG (Fig. 4.3).  
4.2.1.5 Combination Treatment Effects on Secreted VEGF Concentrations. 
Combining resveratrol and EGCG had no effect on VEGF concentrations after two or six day 
treatments (Fig. 4.4). 
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Figure 4.3. VEGF supernatant concentration (as determined by ELISA and expressed as 
ng/ml VEGF/mg total cell protein content) of SKOV-3 (a, c, e) and OVCAR-5 (b, d, f) 
spheroids/clusters treated with various concentrations of EGCG for 2 days (a, b), 4 days (c, 
d) or 6 days (e, f). Data are from three independent experiments carried out in triplicate ± 
SEM. * denotes statistical significance (t-test P<0.05) relative to the control. 
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Figure 4.4. VEGF supernatant concentration (as determined by ELISA and expressed as 
ng/ml VEGF/mg total cell protein content) of SKOV-3 (a, c) and OVCAR-5 (b, d) 
spheroids/clusters treated with 20µM resveratrol, 20µM EGCG or 10µM resveratrol + 
10µM EGCG (combination) for 2 days (a, b) or 6 days (c, d). Data are from three 
independent experiments carried out in triplicate ± SEM. * denotes statistical significance 
(t-test, P < 0.05) relative to the control. 
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4.3.2 IL-8 
4.3.2.1 IL-8 secretion in basal conditions. 
The concentration of IL-8 present in cell media after two, four or six days of drug treatment 
was assessed using a human IL-8 ELISA Kit. An 8 point standard curve was created and the 
amount of IL-8 in each sample was found by comparing the absorbance of the samples to 
the standard curve. The concentrations were then normalised by dividing the amount by 
the total protein of the sample obtained using the BSA protein assay. 
The basal secretion of IL-8 from SKOV-3 cells (typically between 1 and 2 ng/ml/mg) was 
much greater than that from OVCAR-5 which went from below detectable concentrations 
up to 0.1 ng/ml/mg (Fig. 4.5, 4.6, 4.7, 4.8).  
4.3.2.2 Resveratrol Treatment effects on secreted IL-8 concentrations. 
Unlike the VEGF secretion, IL-8 concentration increased with resveratrol treatment (Fig. 
4.5).  The increase in secreted IL-8 in SKOV-3 was time and dosage dependent. Two days of 
resveratrol treatment gave no significant effect, however after 4 and 6 days treatment 
with 10µM resveratrol IL-8 concentrations doubled and after 20µM or 30µM treatment IL-
8 levels tripled (Fig. 4.5 a, c, d). OVCAR-5 IL-8 concentrations also increased from 
undetectable levels after 2 days treatment to between 0.1 and 0.2 ng/ml/mg after 6 days 
treatment (Fig. 4.5 b, f). There was only one statistically significant result in OVCAR-5 IL-8 
levels where the level increased 400% after 4 days treatment with 10µM resveratrol, the 
other increases after stronger doses were not significant due to the large standard error of 
the mean (Fig. 4.5 d, f). 
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Figure 4.5. IL-8 supernatant concentration (as determined by ELISA and expressed as ng/ml 
IL-8/mg total cell protein content) of SKOV-3 (a, c, e) and OVCAR-5 (b, d, f) 
spheroids/clusters treated with various concentrations of resveratrol for 2 days (a, b), 4 
days (c, d) or 6 days (e, f). Data are from four independent experiments carried out in 
triplicate ± SEM. * denotes statistical significance (t-test P<0.05) relative to the control. 
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4.3.2.3 Acetyl Resveratrol Treatment effects on secreted IL-8 
concentrations. 
Both cell lines appear to increase IL-8 secretion in response to acetyl resveratrol treatment 
although OVCAR-5’s response was not significant due to quite large standard errors (Fig. 
4.6). Acetyl resveratrol’s effect on SKOV-3 IL-8 concentrations was time dependent as only 
the 6 day treatment elicited a significant increase. IL-8 secretion was doubled across all 
doses (Fig. 4.6 e). 
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Figure 4.6. IL-8 supernatant concentration (as determined by ELISA and expressed as ng/ml 
IL-8/mg total cell protein content) of SKOV-3 (a, c, e) and OVCAR-5 (b, d, f) 
spheroids/clusters treated with various concentrations of acetyl resveratrol for 2 days (a, 
b), 4 days (c, d) or 6 days (e, f). Data are from three independent experiments carried out 
in triplicate ± SEM. * denotes statistical significance (t-test P<0.05) relative to the control. 
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4.3.2.4 EGCG Treatment Effects on Secreted IL-8 Concentrations. 
EGCG did not affect either cell line at any of the doses tested (Fig. 4.7). 
4.3.2.5 Combination Treatment Effects on Secreted IL-8 Concentrations. 
The combination of resveratrol and EGCG did not have any significant effect on either cell 
line (Fig. 4.8). However, EGCG alone increased IL-8 secretion after 2 days treatment (Fig. 
4.8 a) although this result may be an anomaly as the effect was not seen in either the 6 day 
combination experiment or in the EGCG experiments (Fig. 4.7, Fig. 4.8). 
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Figure 4.7. IL-8 supernatant concentration (as determined by ELISA and expressed as ng/ml 
IL-8/mg total cell protein content) of SKOV-3 (a, c, e) and OVCAR-5 (b, d, f) 
spheroids/clusters treated with various concentrations of EGCG for 2 days (a, b), 4 days (c, 
d) or 6 days (e, f). Data are from three independent experiments carried out in triplicate ± 
SEM. * denotes statistical significance (t-test P<0.05) relative to the control. 
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Figure 4.8. IL-8 supernatant concentration (as determined by ELISA and expressed as ng/ml 
IL-8/mg total cell protein content) of SKOV-3 (a, c) and OVCAR-5 (b, d) spheroids/clusters 
treated with 20µM resveratrol, 20µM EGCG or 10µM resveratrol + 10µM EGCG 
(combination) for 2 days (a, b) or 6 days (c, d). Data are from three independent 
experiments carried out in triplicate ± SEM. * denotes statistical significance (t-test, P < 
0.05) relative to the control. 
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4.4 Discussion. 
It has been established that VEGF production is elevated in tumour cells when compared to 
homeostatic cells and that it is pathologically vital for angiogenesis in many cancers 
(Shimizu et al., 2010). Increased VEGF production by ovarian cancer cells has also been 
associated with poorer prognoses in sufferers (Yu et al., 2013). The correlation between IL-
8 secretion and prognosis of cancer patients is not so well defined. In breast cancer, IL-8 
concentration is possibly a novel maker for tumour aggressiveness in estrogen-receptor 
(ER) positive cells; however it is ER-positive cancers that have the better prognosis (Freund 
et al., 2003). For cervical cancer, elevated IL-8 expression (greater than 1 ng/mg protein) is 
correlated with an extremely poor prognosis (Fujimoto et al., 2000). In ovarian cancer one 
study found that it was not a predictor of prognosis (Lane et al., 2011), whilst another 
linked high production of IL-8 to paclitaxel resistance and thus poor prognosis (Penson et 
al., 2000). The attenuation of the two proteins has also been linked to cell apoptosis and 
tumour growth reduction (Sparmann and Bar-Sagi, 2004, Shimizu et al., 2010, Mikula-
Pietrasik et al., 2012). 
The current study reveals that VEGF secretion is much higher than IL-8 secretion overall, 
this is in line with other studies with typical basal secretion of VEGF being 1-3 ng/ml (Park 
et al., 2007, Dann et al., 2009) and basal IL-8 production between 0 and 400 pg/ml (Freund 
et al., 2003, Trompezinski et al., 2003). In breast and other ovarian cancer lines it has been 
suggested that IL-8 secretion is linked to ER status, with ER positive cell lines producing no 
IL-8 whilst ER negative lines overexpress IL-8 (Freund et al., 2003). However, this study 
suggests that the opposite may be true for these particular immortal lines as IL-8 
producing SKOV-3 is ER positive whilst OVCAR-5 is ER negative and secretes no IL-8. The 
low expression of VEGF in OVCAR-5 may be one reason why its cellular metabolism and 
proliferation was not affected by treatment with resveratrol or acetyl resveratrol. As these 
compounds are attenuating VEGF expression and this decrease is proposed to be 
responsible for the decline in SKOV-3’s metabolism and growth. It can be hypothesised 
that if there is low VEGF secretion to begin with, then any reduction in secretion would not 
make a difference to cell growth. This would then raise the possibility that OVCAR-5 is not 
reliant on VEGF for growth and metastasis, whereas SKOV-3 depends more heavily on 
VEGF. 
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4.4.1 Resveratrol. 
The dose and time dependency of VEGF attenuation by resveratrol in SKOV-3 cells 
correlates with its effect on metabolism and proliferation. Thus, it is suggested that VEGF 
may at least in part be responsible for the afore mentioned response. The relationship 
between VEGF suppression and enhanced apoptosis has been identified in a previous study 
of monolayers of normal endothelial cells treated with 10µM resveratrol for two days 
(Mikula-Pietrasik et al, 2012). Resveratrol at 0.5 –100µM has also been shown to reduce 
VEGF production in endometrial and ovarian cancer cell monolayer cultures after 24 hours 
exposure (Park et al., 2007, Dann et al., 2009). However, the upregulating effect of 
resveratrol on IL-8 secretion in both ovarian cancer cell lines has not been observed 
before. Previous studies on monolayer cultures of other cell lines have typically found that 
resveratrol suppresses IL-8 production (Aggarwal et al., 2004, Mikula-Pietrasik et al., 2012). 
However, Lee et al., 2000, observed that paclitaxel treatment induced IL-8 secretion in 
ovarian cancer; therefore it is possible that resveratrol is exerting this same effect in these 
particular cell lines. This raises the question of whether these cell lines are beginning to 
compensate for the reduction of VEGF, as IL-8 has been implicated in the tumorigenic and 
metastatic potential of other cancers (Xie, 2001). The use of 3D cell cultures in this study 
may represent likely in vivo responses more accurately. Therefore, I cautiously suggest that 
prolonged exposure to doses of at least 30µM resveratrol would be effective in restricting 
ovarian cancer tumour growth and metastasis (this of course would be dependent on the 
cell type of the origin of the cancer). This is a higher concentration and much longer 
exposure time than suggested in previous reports and is possibly due to the different cell 
culturing method used in this study. 
4.4.2 Acetyl resveratrol. 
As mentioned previously acetyl resveratrol was investigated due to the possibility that it 
might be more bioavailable than resveratrol (Liang et al, 2013). However, very little is 
known about the anticarcinogenic properties of acetyl resveratrol and, to the best of my 
knowledge, this is the first study of its effects on VEGF and IL-8 secretion.  Its effect on 
both VEGF and IL-8 secretion were very similar to that of resveratrol, thus once again it is 
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suggested that prolonged exposure to 30µM acetyl resveratrol may attenuate metastasis 
and tumour growth in certain ovarian cancer types. 
4.4.3 EGCG. 
Studies have shown that EGCG is able to attenuate VEGF secretion in different cell types. In 
normal endothelial monolayer cell cultures EGCG downregulates VEGF binding and 
production at low concentrations, thereby inhibiting cell proliferation without inducing 
apoptosis (Kondo et al., 2002, Trompezinski et al., 2003). In several cancer cell monolayer 
cultures, such as endometrial, breast and colorectal cancer, higher doses of EGCG (55-
100µM) decrease VEGF secretion, inhibit cell proliferation and induce apoptosis 
(Sartippour et al., 2002, Dann et al., 2009, Shimizu et al., 2010). Even in an ovarian cancer 
monolayer study using different cell lines to this study 20-40µM EGCG was found to 
decrease VEGF production, supress cell growth and increase apoptosis (Spinella et al, 
2006). There appear to be few investigations into the link between EGCG and IL-8 yet there 
is evidence that EGCG decreases IL-8 secretion in homeostatic cells, although IL-8 
production must first be stimulated with a pro-inflammatory cytokine (Chen et al., 2002, 
Trompezinski et al., 2003). However, in correlation with cellular metabolism and growth 
results in this study VEGF and IL-8 secretion is not affected in either cell line by EGCG 
treatment. 
4.4.4 Resveratrol and EGCG combination. 
Unfortunately once again no synergistic effect was evident between resveratrol and EGCG 
in regards to VEGF and IL-8 secretion. This was somewhat unexpected as previous 
investigations have revealed that resveratrol and EGCG have a synergistic effect in 
combination with other natural products (Suganuma et al., 1999, Conte et al., 2003). 
Furthermore, the polyphenols have been shown to affect multiple cancer growth pathways 
and some of their activity does not overlap (Fig. 4.9) (Hemalswarya and Doble, 2006). 
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Figure 4.9 Proposed molecular targets for resveratrol and EGCG in cancer. 1 - resveratrol 
blocks EGFR. 2 - resveratrol and EGCG inhibit the NF-κB pathway. 3 - resveratrol and EGCG 
inhibit AP-1 pathway. 4 - EGCG blocks the MAPK signalling pathway. Image from 
Hemalswarya and Doble, 2006. 
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Chapter 5  
Signalling Protein Expression. 
5.1 Introduction. 
The results presented in Chapter 4 suggest that VEGF is decreased by resveratrol and 
acetyl resveratrol in ovarian cancer cells grown in 3D cultures.  The next stage in the 
investigation was to investigate the possible mechanisms that may be associated with 
VEGF suppression in spheroids/clusters of ovarian cancer cells. The signalling pathways 
that control cell proliferation, survival, and oncogenesis are of interest in research for the 
development of targeted cancer cell therapy (Rayet and Gelinas, 1999). One such pathway 
that appears to be prominent in cancer cell growth and survival is the NF-κB pathway. 
Since the discovery of NF-κB there has been much research into its transcriptional and 
biological functions, and the mechanisms that control its activity (Athar et al., 2009). The 
secretion of VEGF and IL-8 have been linked to the activation of the NF-κB signalling 
pathway in many types of normal and cancerous cells (Birk et al., 2008, Novotny et al., 
2008, Leychenko et al., 2011). Furthermore, binding sites for NF-κB on or near the 
promoter sequences of VEGF and IL-8 have been identified (Royds et al., 1998, Roebuck 
1999). 
5.1.1 Nuclear Factor-Kappa B (NF-κB). 
5.1.1.1 Background. 
The NF-κB proteins are a small family of inducible transcription factors that include RelA 
(p65), RelB, p-50 and p52 (Rayet and Gelinas, 1999). Nearly all of this family can form 
homo- or heterodimers; it is the p50-RelA heterodimer that is called NF- κB (Rayet and 
Gelinas, 1999). This highly regulated dimer is a positive mediator of T- and B- cell 
development, survival and proliferation (Jost and Ruland, 2007). It is involved in the 
regulation of a variety of cellular processes such as inflammation, immune and stress 
responses, cell growth regulation, as well as oncogenesis and cell transformation (Athar et 
al., 2009). In the inactive state NF-κB is bound and sterically blocked by the inhibitor 
protein IkBα in the cytoplasm (Pervais, 2004). In the active state, which is stimulated by 
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nutrients, growth factors, cytokines and chemokines, several upstream kinases such as 
mitogen-activated protein kinases (MAPK) phosphorylate IκB kinase. This in turn 
phosphorylates IκBα which is then polyubiquitinated and subsequently degraded (Kraft et 
al., 2009). Thus, NF-κB is released, allowing nuclear translocation of the active dimer and 
the activation of gene transcription (Jost and Ruland, 2007). Defects in NF-κB lead to 
increased apoptosis due to its regulation of anti-apoptotic genes. Incorrect regulation of 
the transcription factor has been associated with inflammatory and autoimmune diseases, 
septic shock, viral infection and cancer (Shukla and Singh, 2011). 
5.1.1.2 NF-κB and Cancer. 
Since the identification of NF-κB it has been suspected to be involved in the development 
of some cancers due to its similarity to the oncogene v-Rel (Karin, 2009). Thus far the NF-
κB pathway has been shown to be involved in the survival of numerous cancers such as 
skin, prostate and lung cancer (Shukla and Singh, 2011). Many of these cancers display 
constitutively high levels of NF-κB due to hyperactivation of the signalling pathway or 
inactivating mutations in IκBα (Rayet and Gelinas, 1999). Constitutive activation is a critical 
pathogenic factor in lymphoma and aberrant activation correlates with a poor clinical 
outcome in diffuse large B-cell lymphoma (Jost and Ruland, 2007). Persistent activation of 
NF-κB has also been identified in breast, stomach and thyroid cancers (Rayet and Gelinas, 
1999). However, oncogenic mutations within NF-κB appear to be rare (Karin, 2009) and 
chromosomal aberrations involving NF-κB are infrequently found in lymphomas and 
leukaemias (Rayet and Gelinas, 1999). It has been hypothesised that sustained activation 
of NF-κB is necessary for growth, survival and tumourigenicity of many different tumour 
types through its homeostatic regulation of inflammatory responses and anti-apoptotic 
genes (Karin, 2009). As an example in multiple myeloma cells, supressed NF-κB resulted in 
decreased anti-apoptotic genes cyclin D1, cIAP-2, XIAP, survivin, Bcl2, BclxL, Bfl-1/A1, 
TRAF2 and Akt (Althar et al., 2009) and inflammatory components have been identified in 
the microenvironment of tumours that are not epidemiologically related to inflammation 
(Karin, 2009). Hypoxia has also been identified as an inducer of the NF-κB pathway 
(Schmidt et al., 2007). Ascites induced by the metastatic stages of ovarian cancer is a 
hypoxic condition; therefore, it is proposed that the NF-κB pathway is upregulated and 
integral to the survival of ovarian cancer cells.  
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5.1.1.3 NF-κB and Resveratrol. 
In previous studies it has been reported that resveratrol attenuates the NF-κB pathway in 
breast and pancreatic cancers, as well as in multiple myeloma and acute myeloid 
leukaemia (Pervaiz, 2004, Athar et al., 2009, Goswami and Das, 2009). To date, the targets 
of resveratrol have been identified as IκBα, where it blocks the phosphorylation and 
therefore degradation of the inhibitor (Pervais, 2004), IκB kinase, suppression of IκB kinase 
phosphorylation again results in inhibited degradation of I IκBα (Bianchini and Vainio, 
2003), and perhaps even attenuation of NF-κB itself (Athar et al., 2009).  
 
5.1.2 Aims of Chapter 5. 
This chapter investigates the effect of resveratrol and acetyl resveratrol on the signalling 
proteins pIκBα, NF-κB and pNF-κB. This will demonstrate if the NF-κB signalling pathway 
plays a role in resveratrol and acetyl resveratrol’s ability to reduce VEGF secretion.  
 
 
 
 
 
 
 
 
 
 
 
88 
 
5.2 Methods and Materials. 
Experimental 3D spheroid cell cultures -See Chapter 2 for full method and materials. 
BCA Protein Assay –See Chapter 2 for full method and materials. 
Western Blotting –See Chapter 2 for full method and materials. 
Frozen Sectioning and Immunofluorescence –See Chapter 2 for full method and materials. 
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5.3 Results. 
5.3.1 Six Day NF-κB inhibitor Treatment Effects on Cellular 
Metabolism and Proliferation. 
To investigate if the NF-κB protein is associated with cell viability and growth a specific NF-
κB inhibitor, Bay 1170805, was employed. Cellular metabolism of SKOV-3 
spheroids/clusters was reduced in a dose dependent fashion by treatment with the NF-κB 
inhibitor for 6 days. The lowest concentration of Bay 117085 tested, 10µM, resulted in a 
35% decrease in metabolic rate. Concentrations of 20µM and 30µM inhibitor treatment 
reduced metabolism by 62% and 79% respectively (Fig. 5.1 a). Bay 117085 also caused a 
dose dependent decrease in SKOV-3 cell growth by as much as 52% at 30 µM (Fig. 5.1 c). 
The cell growth and metabolism of the OVCAR-5 cell line was also dose dependently 
adversely affected by NF-κB inhibition, albeit not as strongly as the SKOV-3 cell line (Fig. 
5.1). Metabolic rate was decreased by 40% and 24% with 20µM and 30µM Bay 117085, 
respectively (Fig. 5.1 b). OVCAR-5 cell growth also declined by 18% when treated with 
20µM of inhibitor and by 28% when treated with 30µM of inhibitor (Fig. 5.1 d). 
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Figure 5.1. Relative cellular metabolism (as determined by Alamar Blue assay) and growth 
activity (as determined by a crystal violet assay) of SKOV-3 (a, c) and OVCAR-5 (b, d) 
spheroids/clusters treated with various concentrations of NF-κB inhibitor Bay 117085 for 6 
days. Data are from four independent experiments carried out in triplicate ± SEM. * 
denotes statistical significance (t-test, P < 0.05) relative to the control. 
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5.3.2 Protein expression. 
Western blotting was performed to determine the expression of three signalling proteins 
and one cell cycle protein in SKOV-3 and OVCAR-5 spheroids/clusters exposed for 6 days to 
either resveratrol or acetyl resveratrol. Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) was used as the reference housekeeping protein, due to its relatively constant 
expression in the cell lines being used, despite changing cell conditions. This was 
quantitatively assessed via the density of the GAPDH bands (Fig.5.2 e, 5.5 d, 5.8 d, 5.11 e, 
5.14), and was therefore deemed most appropriate for these analyses. Western blotting of 
alternative housekeeping proteins was carried out but none were as suitable as a 
housekeeping protein (See Appendix).  
 
5.3.2.1 Protein Expression in SKOV-3 spheroids/clusters Treated for 6 days 
with Resveratrol. 
In the SKOV-3 cell line, NF-κB and pNF-κB showed a dose dependant decrease after 6 days 
treatment with resveratrol (Fig. 5.2 b, c). The proportion of phosphorylated NF-κB to non-
phosphorylated NF-κB was between 25 – 28% after 6 days resveratrol treatment. pIκBα 
and PCNA were unaffected by resveratrol treatment (Fig. 5.2 a, d). Immunofluorescence 
showed that NF-κB (stained red) was located in the cytoplasm and the nuclei (stained blue) 
of SKOV-3 cells grown as spheroids/clusters (Fig. 5.3). After 6 days treatment with 20µM 
and 30µM resveratrol there was a noticeable reduction of NF-κB located inside the nuclei 
and an overall reduction of NF-κB expression (Fig. 5.3). Z-stack imaging (not shown) was 
used to confirm that pNF-κB was also located inside nuclei as it was harder to discern than 
NF-κB (Fig. 5.3, Fig. 5.4). There was also a reduction of overall pNF-κB expression and 
nuclear location after 6 days treatment with 30µM resveratrol (Fig. 5.4).  
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Figure 5.2. Effects of resveratrol treatment for 6 days on SKOV-3 spheroids/clusters.  
Western blot and densitometry ratios of (a) pIκBα (b) NF-κB (c) pNF-κB (d) PCNA (e) 
GAPDH. Western blot images are representative of three experiments carried out in 
duplicate. The glycolytic enzyme GAPDH was used as a reference protein and 10 μg of 
protein per well was loaded for each sample. Densitometry ratios are relative to GAPDH, 
whose expression did not change after treatment (e). Results are representative of three 
independent experiments analysed in duplicate. 
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Figure 5.3. Immunofluorescent images of NF-κB in frozen cut sections of SKOV-3 
spheroids/clusters treated with resveratrol for 6 days. NF-κB was stained red (left column) 
and nuclei were stained blue (middle column). 
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Figure 5.4. Immunofluorescent images of pNF-κB in frozen cut sections of SKOV-3 
spheroids/clusters treated with resveratrol for 6 days. pNF-κB was stained red (left 
column) and nuclei were stained blue (middle column). 
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5.3.2.2 Protein Expression in OVCAR-5 spheroids/clusters Treated for 6 days 
with Resveratrol. 
The trend of dose dependent decrease of NF-κB and pNF-κB after 6 days treatment with 
resveratrol was also evident in the OVCAR-5 cell line (Fig. 5.5). There was approximately 5 
times more NF-κB present in the OVCAR-5 cell line compared to SKOV-3 (Fig. 5.2, Fig. 5.5). 
Furthermore, the proportion of phosphorylated NF-κB to non-phosphorylated NF-κB 
expressed by OVCAR-5 was much greater than in SKOV-3, on average it was around 70% 
after resveratrol treatment. Immunofluorescent images of the OVCAR-5 spheroids/clusters 
showed almost no NF-κB or pNF-κB located in the nuclei (Fig. 5.6, Fig. 5.7). The expression 
of NF-κB and pNF-κB did not appear to change after 6 days of resveratrol treatment (Fig. 
5.6, Fig. 5.7). 
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Figure 5.5. Effects of resveratrol treatment for 6 days on OVCAR-5 spheroids/clusters.  
Western blot and densitometry ratios of (a) NF-κB (b) pNF-κB (c) PCNA (d) GAPDH. Western 
blot images are representative of one experiment carried out in duplicate. The glycolytic 
enzyme GAPDH was used as a reference protein and 10 μg of protein per well was loaded 
for each sample. Densitometry ratios are relative to GAPDH, whose expression did not 
change after treatment (d). Results are representative of one experiment analysed in 
duplicate. 
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Figure 5.6. Immunofluorescent images of NF-κB in OVCAR-5 spheroids/clusters treated 
with resveratrol for 6 days. NF-κB was stained red (left column) and nuclei were stained 
blue (right column). 
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Figure 5.7. Immunofluorescent images of pNF-κB in OVCAR-5 spheroids/clusters treated 
with resveratrol for 6 days. pNF-κB was stained red (left column) and nuclei were stained 
blue (right column). 
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5.3.2.3 Protein Expression in SKOV-3 spheroids/clusters Treated for 6 days 
with Acetyl resveratrol. 
pIκBα expression showed a dose dependant increase after 6 days treatment with acetyl 
resveratrol (Fig. 5.8 a). NF-κB and pNF-κB were not affected by the treatment (Fig. 5.8 b, c). 
The proportion of phosphorylation of NF-κB after 6 days acetyl resveratrol treatment was 
between 38 – 43%. Immunofluorescence showed that NF-κB and pNF-κB were located in 
the nuclei and cytoplasm, and their expression did not visibly alter after acetyl resveratrol 
treatment (Fig. 5.9, Fig. 5.10). 
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Figure 5.8. Effects of acetyl resveratrol treatment for 6 days on SKOV-3 spheroids/clusters.  
Western blot and densitometry ratios of (a) pIκBα (b) NF-κB (c) pNF-κB (d) GAPDH. 
Western blot images are representative of three experiments carried out in duplicate. The 
glycolytic enzyme GAPDH was used as a reference protein and 10 μg of protein per well 
was loaded for each sample. Densitometry ratios are relative to GAPDH, whose expression 
did not change after treatment (d). Results are representative of three independent 
experiments analysed in duplicate. 
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Figure 5.9. Immunofluorescent images of NF-κB in frozen cut sections of SKOV-3 
spheroids/clusters treated with acetyl resveratrol for 6 days. NF-κB was stained red (left 
column) and nuclei were stained blue (middle column). 
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Figure 5.10. Immunofluorescent images of pNF-κB in frozen cut sections of SKOV-3 
spheroids/clusters treated with acetyl resveratrol for 6 days. pNF-κB was stained red (left 
column) and nuclei were stained blue (middle column). 
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5.3.2.4 Protein Expression in OVCAR-5 spheroids/clusters Treated for 6 days 
with Acetyl resveratrol. 
A trend of dose dependent decrease of NF-κB after 6 days treatment with acetyl 
resveratrol was evident in the OVCAR-5 cell line (Fig. 5.11). There was approximately 6 
times more NF-κB present in the OVCAR-5 cell line compared to SKOV-3 (Fig. 5.8, Fig. 5.11). 
Furthermore, the proportion of phosphorylated NF-κB to non-phosphorylated NF-κB 
expressed by OVCAR-5 was again much greater than in SKOV-3. Immunofluorescent images 
of the OVCAR-5 spheroids/clusters showed almost no NF-κB or pNF-κB located in the nuclei 
(Fig. 5.12, Fig. 5.13). The expression of NF-κB and pNF-κB did not appear to change after 6 
days of acetyl resveratrol treatment (Fig. 5.12, Fig. 5.13). 
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Figure 5.11. Effects of acetyl resveratrol treatment for 6 days on OVCAR-5 
spheroids/clusters.  Western blot and densitometry ratios of (a) pIκBα (b) NF-κB (c) pNF-κB 
(d) PCNA (e) GAPDH. Western blot images are representative of one experiment carried 
out in duplicate. The glycolytic enzyme GAPDH was used as a reference protein and 10 μg 
of protein per well was loaded for each sample. Densitometry ratios are relative to GAPDH, 
whose expression did not change after treatment (e). Results are representative of one 
experiment analysed in duplicate.  
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Figure 5.12. Immunofluorescent images of NF-κB in OVCAR-5 spheroids/clusters treated 
with acetyl resveratrol for 6 days. NF-κB was stained red (left column) and nuclei were 
stained blue (right column). 
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Figure 5.13. Immunofluorescent images of pNF-κB in OVCAR-5 spheroids/clusters treated 
with acetyl resveratrol for 6 days. pNF-κB was stained red (left column) and nuclei were 
stained blue (right column). 
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5.3.2.5 Protein Expression in SKOV-3 spheroids/clusters Treated for 4 days 
with Resveratrol. 
Western blot analysis showed that treatment of SKOV-3 spheroids/clusters for 4 days with 
resveratrol did not significantly affect any of the proteins of interest (Fig. 5.14). The overall 
expression of pIκBα was at least two fold greater than expression in SKOV-3 
spheroids/clusters treated for 6 days with either resveratrol or acetyl resveratrol (Fig. 5.2, 
Fig. 5.8, Fig. 5.14). 
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Figure 5.14. Effects of resveratrol treatment for 4 days on SKOV-3 spheroids/clusters.  
Western blot and densitometry ratios of (a) pIκBα (b) NF-κB (c) pNF-κB (d) GAPDH. 
Western blot images are representative of two experiments carried out in duplicate. The 
glycolytic enzyme GAPDH was used as a reference protein and 10 μg of protein per well 
was loaded for each sample. Densitometry ratios are relative to GAPDH, whose expression 
did not change after treatment (d). Results are representative of two independent 
experiments analysed in duplicate. 
 
 
109 
 
5.4 Discussion. 
Overall the results show that inhibiting NF-κB does reduce the growth of ovarian cancer 
spheroids/clusters. Therefore, it was a viable pathway to investigate in regards to the 
mechanisms underpinning the anti-cancer effects of resveratrol and acetyl resveratrol. This 
study showed that it is possible that the chemopreventive activity of resveratrol and acetyl 
resveratrol may in part be due to their ability to reduce total expression of NF-κB. 
However, this effect is cell line dependent. 
5.4.1 Treatment effects on signalling proteins. 
Phosphorylation of NF-κB has been shown to increase the transcriptional action of NF-κB 
(Egan et al. 1999); therefore, in this study I looked for expression of both NF-κB and pNF-κB 
in the two cell lines to get a clearer indication of the activity of NF-κB. Western blotting 
revealed that in the SKOV-3 cell line there was a significant dose dependent reduction in 
NF-κB and pNF-κB expression when treated with resveratrol for 6 days. Immunofluorescent 
staining revealed a significant amount of NF-κB and pNF-κB located in the cytoplasm and 
the nucleus of control SKOV-3 cells. Resveratrol treatment appears to reduce the quantity 
of the proteins overall and there is noticeably less in the nuclei. This could suggest that the 
NF-κB signalling pathway may be in part responsible for the production of VEGF in this cell 
line as levels of NF-κB correlate with VEGF secretion. A decrease in NF-κB resulting in 
diminished cell viability has been identified in other cancers and even monolayer cultures 
of ovarian cancer (Alberti et al., 2012). However, this may be the first time the correlation 
has been observed utilising 3D ovarian cancer cultures, providing a possible link between 
NF-κB signalling and early metastasis of ovarian cancer.  
The expression of the NF-κB inhibitor pIκBα was also measured to give an indication as to 
whether resveratrol decreases NF-κB itself or a protein further upstream in the signalling 
cascade. Western blot analysis of pIκBα expression in SKOV-3 suggested that NF-κB is the 
possible target of resveratrol and not pIκBα or other signalling molecules further upstream, 
as pIκBα expression was not attenuated by resveratrol treatment. Unexpectedly, the 
overall expression level of pIκBα in SKOV-3 was very low, as phosphorylation of IκBα is 
purported to be essential for the activation of NF-κB, therefore expression of pIκBα was 
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expected to be similar to NF-κB. There are a few possibilities for what could be taking place 
in the cells; firstly, there is evidence that the ubiquitination and degradation of pIκBα 
occurs rapidly (Karin and Ben-Neriah, 2000), thus after 6 days treatment most may have 
already been degraded. The expression of pIκBα after 4 days treatment with resveratrol 
compared to the pIκBα expression after 6 days with both resveratrol and acetyl resveratrol 
would suggest that rapid degradation of pIκBα is likely as the 4 day expression is at least 
two fold greater.  It has also been suggested that only 10-20% of RelA located in the 
cytoplasm is coupled to IκBα, indicating that there may be a significant pool of RelA that is 
potentially regulated by pathways independent of IκBα (Brasier, 2006). Therefore, it is 
possible that the canonical IκBα pathway is not involved in NF-κB expression in the SKOV-3 
cell line. One potential alternative pathway is the conjugation of RelA to either p105 or 
p100, these are precursors for p50 and p52 respectively, when stimulated the processing 
of the precursor results in the release of the NF-κB subunits that are then free to 
translocate to the nucleus (Karin and Ben-Neriah, 2002). This would mean that there was 
still a high probability that resveratrol affects upstream signalling proteins of an alternate 
pathway and not NF-κB directly.  
Although treatment with acetyl resveratrol did not produce statistically significant 
suppression of either NF-κB or pNF-κB, the overall trend of the western blot and 
immunofluorescence results correlate with the resveratrol results. This suggests that acetyl 
resveratrol may be a viable treatment option. 
Whilst the presence of NF-κB was detected in both cell lines, it is expressed to a much 
greater extent in OVCAR-5 cells than in SKOV-3 cells. However, this high expression of NF-
κB did not translate into high secretion of VEGF or IL-8. Although there does appear to be a 
dose dependent reduction of NF-κB in OVCAR-5 after 6 days treatment with resveratrol, 
the expression of the protein is still high even after treatment with the highest dose of 
resveratrol. Immunofluorescent staining of NF-κB and pNF-κB showed no obvious change 
in the density or distribution of the proteins for the various treatment concentrations. 
Furthermore, there were limited levels of NF-κB or pNF-κB in the nuclei of the OVCAR-5 
cells. This indicates that most of the NF-κB is in the cytoplasm and therefore inactive. 
Supporting this is the low expression of pIκBα in OVCAR-5 cells. Assuming that the 
canonical NF-κB pathway is dominant in OVCAR-5, low pIκBα suggests that IκBα may be 
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intact and supressing NF-κB activation. However, this is by no means definitive as western 
blots of OVCAR-5 proteins were only performed once due to the lack of response in 
previous experiments and time limitations, therefore statistical analysis was not possible 
and the various possibilities regarding IκBα expression in SKOV-3 also apply to OVCAR-5.  
Surprisingly the proportion of phosphorylated NF-κB compared to non-phosphorylated NF-
κB was much higher in OVCAR-5 than in SKOV-3. This was unexpected as phosphorylation 
of NF-κB is purported to induce transcriptional activity and as noted above high NF-κB 
expression in OVCAR-5 did not translate into the expression of the two more common 
products of NF-κB activity, IL-8 and VEGF. However, even though NF-κB’s transcriptional 
activity is increased by phosphorylation it has no effect on translocation of NF-κB (Egan et 
al., 1999), so increased activity of NF-κB may not automatically be correlated with 
phosphorylation. There is also the possibility that the detected phosphorylation is actually 
attached to an unprocessed precursor of p50 or p52 complexed with RelA as 
phosphorylation of the precursor is the signal for post-translational modification of the 
precursor, thus a high proportion of inactivated pNF-κB located in the cytoplasm is possible 
(Gilmore, 2006). Another reasonable explanation for the increased pNF-κB expression is 
that OVCAR-5 is deficient in IKKβ, which is an upstream kinase in the NF-κB signalling 
pathway responsible for the nuclear translocation of NF-κB (Sizemore et al., 2002). NF-κB 
would be phosphorylated by IKKα but then unable to enter the nucleus.  
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Chapter 6  
Conclusions. 
6.1 Main conclusions. 
The high mortality rate of ovarian cancer is due to a lack of early detection and its 
uncommon mode of dissemination. Current treatment options are very harsh and there is 
a high incidence of developed resistance (Lengyel, 2010). Therefore, the need for 
alternative chemopreventive and chemotherapeutic agents is urgent. Anti-tumour 
properties have been identified in many natural compounds present in food, of these 
resveratrol and EGCG have been shown to be quite effective in reducing cancer growth 
(Athar et al., 2009).  
This study has demonstrated that resveratrol and the resveratrol analogue acetyl 
resveratrol are effective food compounds in reducing the cellular metabolism and growth 
of certain sub-types of ovarian cancer cells through prolonged exposure to concentrations 
that are possible for a person to ingest through their daily diet. EGCG on the other hand, 
does not appear to be able to affect the growth of ovarian cancer. Therefore, resveratrol 
and acetyl resveratrol are viable candidates for possible treatment of certain sub-types of 
ovarian cancer. 
This investigation has also provided some insight into the mechanisms underlying the anti-
cancer property of resveratrol and acetyl resveratrol. This study has shown that NF-κB 
levels and VEGF secretion correlate to the reduction of cell growth of ovarian cancer 
treated with resveratrol and acetyl resveratrol. These data suggest that NF-κB signalling 
may play a role in the secretion of VEGF which in turn possibly sustains cell viability and 
growth of free floating ovarian cancer cells in the peritoneal cavity. The association of NF-
κB and VEGF has also been noticed in clinical patient tumours. 
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6.2 Future Research. 
As EGCG had been shown to be effective in reducing the growth of ovarian and other 
cancers in monolayer cultures as well as animal models, further work could be undertaken 
to investigate why it did not affect ovarian cancer spheroids/clusters. One plausible 
possibility is that the concentration of EGCG used in this study was not high enough to 
elicit an effect, meaning that the average dietary intake of EGCG would not be effective in 
reducing the spread of this type of cancer. Another is that EGCG treatment at these dosage 
levels require a longer time period to be effectual, this would mean that dietary intake of 
the levels of EGCG utilised in this study may still be beneficial in restricting the metastasis 
of ovarian cancer. 
Due to the resveratrol and acetyl resveratrol effects being cell line specific it would be 
prudent to test the treatments on a much wider range of cell lines to determine how 
effectual the treatments are overall in ovarian cancer. Also an investigation into the 
bioavailability of acetyl resveratrol is now justified. As it is suggested that acetyl resveratrol 
should be more bioavailable than resveratrol and the analogue has now been shown to be 
chemotherapeutic in its current structural form. 
It is very interesting to note that resveratrol and acetyl resveratrol can reduce VEGF but 
the cancer cells secrete more IL-8 in response. Both of these peptides are crucial for 
angiogenic activity in solid tumours. This suggests that cancer cells are possibly 
compensating for the blocked pathway by producing alternative angiogenic molecules. 
Finally, there is more work to be done to better elucidate the mechanisms of resveratrol’s 
effects. The activity of proteins further upstream of pIκBα as well as the abundance of IκBα 
could be studied in SKOV-3 cells to better understand the true target of resveratrol. 
Furthermore, proteins involved in other signalling pathways such as the non-canonical NF-
κB or could be investigated in OVCAR-5 cells. This would provide insight into the 
mechanisms of resveratrol resistant ovarian cancer sub-types and aid the development of 
more effective treatments. 
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Appendix. 
Table A1: Reagents utilised in this study. 
Alamar Blue Invitrogen, CA, USA 
Trypsin-EDTA Gibco, Life Technologies 
MEM Gibco, Life Technologies 
FBS Gibco, Life Technologies 
PenStrep Gibco, Life Technologies 
Glutamax Gibco, Life Technologies 
Fungizone Gibco, Life Technologies 
DMEM Gibco, Life Technologies 
Trypsin powder Gibco, Life Technologies 
EDTA Gibco, Life Technologies 
Crystal Violet Gibco, Life Technologies 
Resveratrol  Biotevia, USA 
Acetyl-resveratrol  Biotevia, USA 
EGCG  Sigman, New Zealand 
Bay 117085 (NF-kB inhibitor) Santa Cruz, USA  
DMSO BDH Ltd, Poole, England 
NaHCO₃ BDH Ltd, Poole, England 
Tween-20 BioRad Laboratories, CA, USA 
BSA Gibco, Life Technologies 
Ultra-TMB  Thermo Scientific, Illinois, USA 
NaN₃ BDH Ltd, Poole, England 
SDS BioRad Laboratories, CA, USA 
Tris Invitrogen, CA, USA 
Protease inhibitor tablet Thermo Scientific, Illinois, USA 
EDTA BDH Ltd, Poole, England 
Methanol Ajax Finechem Pty Ltd, NZ 
Ethanol Technical Grade 
Concentrated HCl  Ajax Finechem Pty Ltd, NZ 
Skim Milk powder Pam's, Australia 
Na₂HPO₄ BDH Ltd, Poole, England 
NaH₂PO₄ BDH Ltd, Poole, England 
KCl BDH Ltd, Poole, England 
NaCl Ajax Finechem Pty Ltd, NZ 
30% Acrylamide BioRad Laboratories, CA, USA 
TEMED BioRad Laboratories, CA, USA 
(NH₄)S₂O₈ BioRad Laboratories, CA, USA 
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NaOH BDH Ltd, Poole, England 
Glycine Sigma-Aldrich LTD, NZ 
Aniline blue Sigma-Aldrich LTD, NZ 
CryO-Z-T Ted Pella Inc, USA 
p-phenylenediamine Sigma-Aldrich LTD, NZ 
Hoechst 33342 Invitrogen, NZ 
  
 
Table A2: Primary antibodies used for western blots and immunofluorescence. 
Primary Type Concentration 
Blocking 
Solution Company 
CK-18 Mouse 1/500 5% Skim milk  Santa Cruz Biotechnology, USA 
SOD-1 Rabbit 1/500 4% BSA  Santa Cruz Biotechnology, USA 
Ribosomal Protein 
L13A Mouse 1/500 1% BSA  Santa Cruz Biotechnology, USA 
GAPDH Rabbit 1/1000 5% Skim milk  Santa Cruz Biotechnology, USA 
PCNA Mouse 1/500 5% Skim milk  Santa Cruz Biotechnology, USA 
pIκBα Mouse  1/500 2% BSA  Santa Cruz Biotechnology, USA 
NF-κB Rabbit  1/500 2% BSA  Santa Cruz Biotechnology, USA 
pNF-κB Rabbit  1/500 5% Skim milk  Santa Cruz Biotechnology, USA 
 
 
Table A3: Secondary antibodies used for western blots. 
Secondary Type Concentration Company 
Mouse Donkey 1/10000 
Santa Cruz Biotechnology, 
USA 
Rabbit Goat 1/10000 
Cell Signalling Technology, 
USA 
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Figure A1: Trial of other potential housekeeping proteins. Images are representative of two 
trials carried out in duplicate. 10µg of protein per well was loaded for each sample. 
Samples from the 6 day resveratrol treatments were used for the trial. 
 
